

# Immunological Effects of Conventional Chemotherapy

Cancer Cell

28, 690-714

DOI: [10.1016/j.ccell.2015.10.012](https://doi.org/10.1016/j.ccell.2015.10.012)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Co-delivery of doxorubicin and recombinant plasmid pHSP70-Plk1-shRNA by bacterial magnetosomes for osteosarcoma therapy. International Journal of Nanomedicine, 2016, Volume 11, 5277-5286.	3.3	39
2	Next generation metronomic chemotherapy” report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6”8 May 2016, Mumbai. Ecancermedicalsecience, 2016, 10, 689.	0.6	10
3	The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. Vaccines, 2016, 4, 43.	2.1	35
4	Tissue-Associated Bacterial Alterations in Rectal Carcinoma Patients Revealed by 16S rRNA Community Profiling. Frontiers in Cellular and Infection Microbiology, 2016, 6, 179.	1.8	125
5	Enhanced Therapeutic Efficacy in Cancer Patients by Short-term Fasting: The Autophagy Connection. Frontiers in Oncology, 2016, 6, 242.	1.3	30
6	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell, 2016, 30, 147-160.	7.7	410
7	Challenges and opportunities”for checkpoint blockade in T-cell lymphoproliferative disorders. , 2016, 4, 95.		18
8	A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer Journal, 2016, 6, e511-e511.	2.8	37
9	Immunotherapy of colorectal cancer: new perspectives after a long path. Immunotherapy, 2016, 8, 1281-1292.	1.0	19
10	Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood, 2016, 128, 3113-3124.	0.6	107
11	Upregulation of programmed cell death ligand 1 promotes resistance response in non”small”cell lung cancer patients treated with neo”adjuvant chemotherapy. Cancer Science, 2016, 107, 1563-1571.	1.7	147
12	Immune Therapy for Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2016, 22, 334-341.	1.0	16
14	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. OncoImmunology, 2016, 5, e1160193.	2.1	11
15	STAT3 inhibition for cancer therapy: Cell-autonomous effects only?. OncoImmunology, 2016, 5, e1126063.	2.1	12
16	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends in Immunology, 2016, 37, 462-476.	2.9	232
17	Microbiome and Anticancer Immunosurveillance. Cell, 2016, 165, 276-287.	13.5	366
18	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 2016, 16, 275-287.	12.8	2,133
19	Distinct Effects of Adipose-Derived Stem Cells and Adipocytes on Normal and Cancer Cell Hierarchy. Molecular Cancer Research, 2016, 14, 660-671.	1.5	9

#	ARTICLE	IF	CITATIONS
20	Endoplasmic Reticulum Stress and the Hallmarks of Cancer. <i>Trends in Cancer</i> , 2016, 2, 252-262.	3.8	406
21	Thermoneutrality, Mice, and Cancer: A Heated Opinion. <i>Trends in Cancer</i> , 2016, 2, 166-175.	3.8	86
22	Mitochondrial Permeability Transition: New Findings and Persisting Uncertainties. <i>Trends in Cell Biology</i> , 2016, 26, 655-667.	3.6	172
23	Dying cell recognition shapes the pathophysiology of cell death. <i>Cell Death and Differentiation</i> , 2016, 23, 913-914.	5.0	1
24	T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. <i>Blood</i> , 2016, 128, 1081-1092.	0.6	120
25	A transplant immunome screening platform defines a targetable epitope fingerprint of multiple myeloma. <i>Blood</i> , 2016, 127, 3202-3214.	0.6	7
26	Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2926-2935.	1.9	50
27	Mouse models in oncoimmunology. <i>Nature Reviews Cancer</i> , 2016, 16, 759-773.	12.8	267
28	Immunosuppressive T cells foster pancreatic carcinogenesis. <i>Oncolmmunology</i> , 2016, 5, e1237328.	2.1	11
29	CCR2 Influences T Regulatory Cell Migration to Tumors and Serves as a Biomarker of Cyclophosphamide Sensitivity. <i>Cancer Research</i> , 2016, 76, 6483-6494.	0.4	64
30	The genomic landscape of breast cancer and its interaction with host immunity. <i>Breast</i> , 2016, 29, 241-250.	0.9	194
31	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncology</i> , 2016, 17, 1497-1508.	5.1	1,279
32	Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8 <sup>+</sup> T cells. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2519-2522.	1.4	6
33	Chemotherapy remains an essential element of personalized care for persons with lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1829-1835.	0.6	83
34	Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma. <i>Oncolmmunology</i> , 2016, 5, e1208876.	2.1	26
35	Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4 <sup>+</sup> tumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2016, 5, e1216289.	2.1	12
36	Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. <i>Immunity</i> , 2016, 45, 1135-1147.	6.6	510
37	The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 661-671.	1.1	297

#	ARTICLE	IF	CITATIONS
38	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolimmunology</i> , 2016, 5, e1214790.	2.1	64
39	Pharmacokinetics and Pharmacogenetics of Metronomics. , 2016, , 189-207.		0
40	Characteristics and Significance of the Pre-metastatic Niche. <i>Cancer Cell</i> , 2016, 30, 668-681.	7.7	767
41	Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. <i>Cancer Biology and Therapy</i> , 2016, 17, 1213-1220.	1.5	52
42	Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 895-902.	1.6	134
43	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 165-202.	0.2	30
44	Immunological Mechanisms in Breast Cancer - from Bench to Bedside. <i>Breast Care</i> , 2016, 11, 93-94.	0.8	0
45	Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. <i>Cancer Research</i> , 2016, 76, 3122-3126.	0.4	47
46	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. <i>Immunity</i> , 2016, 44, 1255-1269.	6.6	797
47	Highly Integrated Nano-Platform for Breaking the Barrier between Chemotherapy and Immunotherapy. <i>Nano Letters</i> , 2016, 16, 4341-4347.	4.5	96
48	Unchaining NK cell-mediated anticancer immunosurveillance. <i>Nature Immunology</i> , 2016, 17, 746-747.	7.0	1
49	Prevention of breast cancer by RANKL/RANK blockade. <i>Cell Research</i> , 2016, 26, 751-752.	5.7	5
50	Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. <i>Briefings in Bioinformatics</i> , 2016, 18, bbw051.	3.2	57
51	An amphiphilic block copolymer conjugated with carborane and a NIR fluorescent probe for potential imaging-guided BNCT therapy. <i>Polymer Chemistry</i> , 2016, 7, 4411-4418.	1.9	29
52	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>Oncolimmunology</i> , 2016, 5, e1139275.	2.1	21
53	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. , 2016, 166, 9-29.		33
54	Anticancer metal drugs and immunogenic cell death. <i>Journal of Inorganic Biochemistry</i> , 2016, 165, 71-79.	1.5	107
55	The oncolytic peptide LTX-315 triggers immunogenic cell death. <i>Cell Death and Disease</i> , 2016, 7, e2134-e2134.	2.7	90

#	ARTICLE	IF	CITATIONS
56	Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. <i>Annals of Oncology</i> , 2016, 27, 1190-1198.	0.6	153
57	Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. <i>Seminars in Immunology</i> , 2016, 28, 54-63.	2.7	47
58	Combinatorial immunotherapy strategies for hepatocellular carcinoma. <i>Current Opinion in Immunology</i> , 2016, 39, 103-113.	2.4	52
59	The Basis of Oncoimmunology. <i>Cell</i> , 2016, 164, 1233-1247.	13.5	671
60	Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>OncolImmunology</i> , 2016, 5, e1149674.	2.1	46
61	First oncolytic virus approved for melanoma immunotherapy. <i>OncolImmunology</i> , 2016, 5, e1115641.	2.1	247
62	Extracellular purines, purinergic receptors and tumor growth. <i>Oncogene</i> , 2017, 36, 293-303.	2.6	428
63	Elements of cancer immunity and the cancer—immune set point. <i>Nature</i> , 2017, 541, 321-330.	13.7	3,558
64	Tumour-associated macrophages as treatment targets in oncology. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 399-416.	12.5	2,667
65	Targeted Therapy and Immunosuppression in the Tumor Microenvironment. <i>Trends in Cancer</i> , 2017, 3, 19-27.	3.8	57
66	Ovarian cancer and the immune system. <i>Gynecologic Oncology Reports</i> , 2017, 19, 57-58.	0.3	16
67	Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 428-439.	1.9	25
68	Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation. <i>Cancer Research</i> , 2017, 77, 1310-1321.	0.4	32
69	Breast Cancer Immunology and Immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2017, 331, 1-53.	1.6	47
70	Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. <i>Molecular Oncology</i> , 2017, 11, 358-372.	2.1	43
71	Immunotherapy comes of age: Immune aging & checkpoint inhibitors. <i>Journal of Geriatric Oncology</i> , 2017, 8, 229-235.	0.5	108
72	Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. <i>Cancer Research</i> , 2017, 77, 2292-2305.	0.4	111
73	The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. <i>Clinical Epigenetics</i> , 2017, 9, 4.	1.8	33

#	ARTICLE	IF	CITATIONS
74	Reactivation of dormant anti-tumor immunity â€“ a clinical perspective of therapeutic immune checkpoint modulation. <i>Cell Communication and Signaling</i> , 2017, 15, 5.	2.7	34
75	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017, 23, 3711-3720.	3.2	710
76	Preface. <i>Methods in Enzymology</i> , 2017, 587, xxiii-xxix.	0.4	2
77	Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine. <i>Cell Discovery</i> , 2017, 3, 17007.	3.1	43
78	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. <i>Oncolmunology</i> , 2017, 6, e1314424.	2.1	106
79	Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. <i>Neuro-Oncology</i> , 2017, 19, 930-939.	0.6	65
80	Proteasome Inhibitorâ€“Loaded Micelles Enhance Antitumor Activity Through Macrophage Reprogramming by NF-Î²B Inhibition. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2438-2446.	1.6	9
81	Preface. <i>Methods in Enzymology</i> , 2017, 588, xxv-xxxi.	0.4	0
82	Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8 <sup>+</sup> T cells. <i>Oncolmunology</i> , 2017, 6, e1318234.	2.1	12
83	IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1049-1058.	2.0	32
84	Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination. <i>Oncolmunology</i> , 2017, 6, e1338995.	2.1	24
85	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. <i>Oncolmunology</i> , 2017, 6, e1339856.	2.1	8
86	Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. <i>Molecular Cancer</i> , 2017, 16, 99.	7.9	129
87	Autophagy in natural and therapy-driven anticancer immunosurveillance. <i>Autophagy</i> , 2017, 13, 2163-2170.	4.3	52
88	Heavy Metal to Rock the Immune Infiltrate. <i>Trends in Immunology</i> , 2017, 38, 539-541.	2.9	9
89	Prospects for combining targeted and conventional cancer therapy with immunotherapy. <i>Nature Reviews Cancer</i> , 2017, 17, 286-301.	12.8	742
90	Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 701-716.	0.9	35
91	Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. <i>Immunotherapy</i> , 2017, 9, 451-460.	1.0	12

#	ARTICLE	IF	CITATIONS
92	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89
93	Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. Lancet, The, 2017, 389, 2430-2442.	6.3	640
94	The complement system is also important in immunogenic cell death. Nature Reviews Immunology, 2017, 17, 143-143.	10.6	6
95	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology, 2017, 49, 141-155.	0.3	112
96	NIR imaging-guided combined photodynamic therapy and chemotherapy by a pH-responsive amphiphilic polypeptide prodrug. Biomaterials Science, 2017, 5, 313-321.	2.6	48
97	Integration of nano drug-delivery system with cancer immunotherapy. Therapeutic Delivery, 2017, 8, 987-1000.	1.2	34
98	A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody) Tj ETQq0 0 0 rgBT /Overlock 10 35-39.	1.1	16
99	Immune recognition of irradiated cancer cells. Immunological Reviews, 2017, 280, 220-230.	2.8	73
100	Mechanisms regulating T-cell infiltration and activity in solid tumors. Annals of Oncology, 2017, 28, xii18-xii32.	0.6	276
101	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell, 2017, 170, 927-938.e20.	13.5	368
102	Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy. Nano Letters, 2017, 17, 6366-6375.	4.5	202
103	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology, 2017, 6, e1371896.	2.1	36
104	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	2.1	62
105	Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. Human Vaccines and Immunotherapeutics, 2017, 13, 2561-2574.	1.4	91
106	Contrasting effects of cyclophosphamide on anti-CTLA-4 associated protein 4 blockade therapy in two mouse tumor models. Cancer Science, 2017, 108, 1974-1984.	1.7	35
107	Nutrition, inflammation and cancer. Nature Immunology, 2017, 18, 843-850.	7.0	313
108	The immune contexture in cancer prognosis and treatment. Nature Reviews Clinical Oncology, 2017, 14, 717-734.	12.5	1,590
109	Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. OncoImmunology, 2017, 6, e1342918.	2.1	90

#	ARTICLE	IF	CITATIONS
110	Mevalonate metabolism governs cancer immune surveillance. <i>Oncolimmunology</i> , 2017, 6, e1342917.	2.1	29
111	The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy. <i>Trends in Cancer</i> , 2017, 3, 643-658.	3.8	152
112	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. <i>Oncolimmunology</i> , 2017, 6, e1363139.	2.1	60
113	Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. <i>European Journal of Pediatrics</i> , 2017, 176, 1163-1172.	1.3	11
114	Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	33
115	Blinatumomab bridges the gap between leukemia and immunity. <i>Oncolimmunology</i> , 2017, 6, e1358335.	2.1	5
116	Control of Metastasis by NK Cells. <i>Cancer Cell</i> , 2017, 32, 135-154.	7.7	549
117	Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma. <i>Oncology Reports</i> , 2018, 39, 151-159.	1.2	39
118	Trial watch: DNA-based vaccines for oncological indications. <i>Oncolimmunology</i> , 2017, 6, e1398878.	2.1	30
119	Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives. <i>Colorectal Cancer</i> , 2017, 6, 23-31.	0.8	1
120	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. <i>Cancer Letters</i> , 2017, 405, 29-37.	3.2	93
121	Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 17-24.	3.2	23
122	Altered CD8+ T-Cell Lymphocyte Function and TC1 Cell Stemness Contribute to Enhanced Malignant Tumor Properties in Murine Models of Sleep Apnea. <i>Sleep</i> , 2017, 40, .	0.6	33
123	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 5-15.	3.2	48
124	The importance of correctly timing cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 87-103.	1.4	26
125	Cell Cycle Synchronization. <i>Methods in Molecular Biology</i> , 2017, , .	0.4	5
126	Ovarian Cancers. , 2017, , .		1
127	Immunogenic cell death in cancer and infectious disease. <i>Nature Reviews Immunology</i> , 2017, 17, 97-111.	10.6	2,000



#	ARTICLE	IF	CITATIONS
128	Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 247-258.	12.5	261
129	Image Cytofluorometry for the Quantification of Ploidy and Endoplasmic Reticulum Stress in Cancer Cells. <i>Methods in Molecular Biology</i> , 2017, 1524, 53-64.	0.4	8
130	Molecular mechanisms involved in dendritic cell dysfunction in cancer. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 761-776.	2.4	77
131	Cardiac glycosides: From molecular targets to immunogenic cell death. <i>Biochemical Pharmacology</i> , 2017, 125, 1-11.	2.0	86
132	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 65-85.	157.7	344
133	Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 925-934.	3.2	125
134	Metal drugs become targeted. <i>ESMO Open</i> , 2017, 2, e000239.	2.0	14
135	Progress in Vaccine Therapies for Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 315-330.	0.8	11
136	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	9
137	Informatics for cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, xii56-xii73.	0.6	19
138	Tumor Immuno-Environment in Cancer Progression and Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 1-18.	0.8	31
139	Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 91-104.	0.8	26
140	Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab. <i>Scientific Reports</i> , 2017, 7, 18027.	1.6	21
141	Water-soluble polyacetylene: a promising tool for sustainable drug delivery?. <i>Therapeutic Delivery</i> , 2017, 8, 929-932.	1.2	1
142	Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1295-1306.	2.0	11
143	Phenotypic and clinical characterization of low density neutrophils in patients with advanced lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 90969-90978.	0.8	28
144	Cancer Immunoprevention and Public Health. <i>Frontiers in Public Health</i> , 2017, 5, 101.	1.3	10
145	The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2227.	1.8	30

#	ARTICLE	IF	CITATIONS
146	High-Throughput Quantification of GFP-LC3+ Dots by Automated Fluorescence Microscopy. <i>Methods in Enzymology</i> , 2017, 587, 71-86.	0.4	20
147	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1918.	2.2	72
148	RAC3 influences the chemoresistance of colon cancer cells through autophagy and apoptosis inhibition. <i>Cancer Cell International</i> , 2017, 17, 111.	1.8	20
149	The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?. <i>Cancer Biology and Medicine</i> , 2017, 14, 341.	1.4	4
150	BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligands. <i>Oncotarget</i> , 2017, 8, 64344-64357.	0.8	24
151	From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. <i>World Journal of Clinical Oncology</i> , 2017, 8, 37.	0.9	64
152	Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors. <i>Oncotarget</i> , 2017, 8, 53730-53739.	0.8	24
153	Gene expression profiles for a prognostic immunoscore in gastric cancer. <i>British Journal of Surgery</i> , 2018, 105, 1338-1348.	0.1	188
154	Oncolytic viruses as engineering platforms for combination immunotherapy. <i>Nature Reviews Cancer</i> , 2018, 18, 419-432.	12.8	288
155	Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity. <i>Clinical Cancer Research</i> , 2018, 24, 3560-3571.	3.2	72
156	Targeting autophagy in cancer. <i>Cancer</i> , 2018, 124, 3307-3318.	2.0	484
157	Molecular Signatures of Regression of the Canine Transmissible Venereal Tumor. <i>Cancer Cell</i> , 2018, 33, 620-633.e6.	7.7	37
158	The gut microbiota influences anticancer immunosurveillance and general health. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 382-396.	12.5	389
159	Combining chemotherapy with PD-1 blockade in NSCLC. , 2018, 186, 130-137.		97
160	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolimmunology</i> , 2018, 7, e1433982.	2.1	38
161	Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies. <i>Cell Systems</i> , 2018, 6, 343-354.e5.	2.9	40
162	Epigenetic anticancer agents cause HMGB1 release <i>in vivo</i> . <i>Oncolimmunology</i> , 2018, 7, e1431090.	2.1	12
163	The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 191-194.	1.1	5

#	ARTICLE	IF	CITATIONS
164	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1433981.	2.1	167
165	The potentially conflicting cell autonomous and cell non-autonomous functions of autophagy in mediating tumor response to cancer therapy. <i>Biochemical Pharmacology</i> , 2018, 153, 46-50.	2.0	7
166	eIF2 $\gamma$ phosphorylation is pathognomonic for immunogenic cell death. <i>Cell Death and Differentiation</i> , 2018, 25, 1375-1393.	5.0	162
167	Spermidine in health and disease. <i>Science</i> , 2018, 359, .	6.0	616
168	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 1308-1320.	0.4	238
169	Therapeutic Strategies for Breast Cancer. , 2018, , 315-330.e7.		5
170	Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting. , 2018, , 579-591.		0
171	The Secrets of T Cell Polarization. , 2018, , 69-95.		0
172	A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer. <i>Oncolmmunology</i> , 2018, 7, e1371895.	2.1	35
173	Inhibitors of the PD-1 Pathway in Tumor Therapy. <i>Journal of Immunology</i> , 2018, 200, 375-383.	0.4	112
174	The efficacy and safety of anti- $\text{PD-L1}$ antibodies combined with chemotherapy or $\text{CTLA-4}$ antibody as a first-line treatment for advanced lung cancer. <i>International Journal of Cancer</i> , 2018, 142, 2344-2354.	2.3	47
175	Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells. <i>Cancer Cell</i> , 2018, 33, 862-873.e5.	7.7	133
176	Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. <i>British Journal of Cancer</i> , 2018, 118, 1329-1336.	2.9	75
177	Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. <i>British Journal of Cancer</i> , 2018, 118, 1322-1328.	2.9	26
178	Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer. <i>Oncolmmunology</i> , 2018, 7, e1457600.	2.1	20
180	Low-Protein Diet Induces IRE1 $\gamma$ -Dependent Anticancer Immunosurveillance. <i>Cell Metabolism</i> , 2018, 27, 828-842.e7.	7.2	99
181	Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. <i>Oral Oncology</i> , 2018, 80, 100-102.	0.8	6
182	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. <i>Immunity</i> , 2018, 48, 417-433.	6.6	416

#	ARTICLE	IF	CITATIONS
183	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patientsâ€™ A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2018, 149, 371-380.	0.6	11
184	ImmunoScore Signature. <i>Annals of Surgery</i> , 2018, 267, 504-513.	2.1	409
185	Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 95-109.	1.2	50
186	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	4.3	303
187	Immunochemotherapy mediated by thermosponge nanoparticles for synergistic anti-tumor effects. <i>Journal of Controlled Release</i> , 2018, 269, 322-336.	4.8	50
188	Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 246-255.	0.4	127
189	Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. <i>Immunotherapy</i> , 2018, 10, 93-105.	1.0	86
190	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
191	Overcoming Immune Suppression in the Tumor Microenvironment: Implications for Multi-modal Therapy. , 2018, , 13-38.		0
192	CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy. , 2018, , 23-39.		7
193	The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer. <i>Oncolimmunology</i> , 2018, 7, e1409321.	2.1	15
194	Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials. <i>Oncolimmunology</i> , 2018, 7, e1408744.	2.1	26
195	Immune checkpoint inhibitors in advanced nonâ€™small cell lung cancer. <i>Cancer</i> , 2018, 124, 248-261.	2.0	94
196	Mitochondrial metabolism and cancer. <i>Cell Research</i> , 2018, 28, 265-280.	5.7	818
198	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. <i>Current Cancer Research</i> , 2018, , 1-28.	0.2	0
199	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. <i>Current Cancer Research</i> , 2018, , 243-280.	0.2	0
200	Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice. <i>Blood</i> , 2018, 131, 202-214.	0.6	40
201	Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. <i>Lung Cancer</i> , 2018, 115, 12-20.	0.9	131

#	ARTICLE	IF	CITATIONS
202	Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. <i>Seminars in Cancer Biology</i> , 2018, 52, 166-177.	4.3	11
203	Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment. <i>Cancer Science</i> , 2018, 109, 54-64.	1.7	60
204	Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 7-24.	1.0	23
206	Combination Immunotherapy Development in Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 197-207.	1.8	39
207	A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 3575-3584.	0.6	36
208	Immunotherapy in treatment naïve advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S412-S421.	0.6	13
209	Immunotherapy in the Asiatic population: any differences from Caucasian population?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1482-S1493.	0.6	42
210	Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189. <i>Journal of Thoracic Disease</i> , 2018, 10, 5186-5189.	0.6	1
211	Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer. <i>Oncology Letters</i> , 2019, 17, 1547-1550.	0.8	0
212	First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. <i>Journal of Oncology Practice</i> , 2018, 14, 529-535.	2.5	41
214	Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?. <i>Cureus</i> , 2018, 10, e3254.	0.2	9
215	Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 2759.	2.2	58
216	Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. <i>Current Oncology Reports</i> , 2018, 20, 94.	1.8	43
218	Chemotherapy and tumor immunity. <i>Science</i> , 2018, 362, 1355-1356.	6.0	36
219	Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881559.	1.4	38
220	PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 17-32.	3.3	72
221	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
222	Induction of immunosuppressive functions and NF- $\kappa$ B by FLIP in monocytes. <i>Nature Communications</i> , 2018, 9, 5193.	5.8	45

#	ARTICLE	IF	CITATIONS
223	Effects of Chemotherapy on the Leucocyte Infiltration in Periodontal Tissues of Cancer Patients: A Preliminary Study. <i>Internal Medicine: Open Access</i> , 2018, 08, .	0.0	0
225	Challenges facing nanotoxicology and nanomedicine due to cellular diversity. <i>Clinica Chimica Acta</i> , 2018, 487, 186-196.	0.5	17
226	An NIR-Guided Aggregative and Self-Immolative Nanosystem for Efficient Cancer Targeting and Combination Anticancer Therapy. <i>Molecular Pharmaceutics</i> , 2018, 15, 4985-4994.	2.3	6
227	Multifunctional Cargo-Free Nanomedicine for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2963.	1.8	21
228	Apoptosis and necroptosis in the liver: a matter of life and death. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 738-752.	8.2	364
229	Immunotherapy-based combinations: an update. <i>Current Opinion in Oncology</i> , 2018, 30, 345-351.	1.1	25
230	Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. <i>Cytotherapy</i> , 2018, 20, 1309-1323.	0.3	16
231	Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. <i>Cell Death and Disease</i> , 2018, 9, 1086.	2.7	20
232	Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology. <i>Frontiers in Oncology</i> , 2018, 8, 430.	1.3	57
233	Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. <i>Cancer Research</i> , 2018, 78, 5729-5730.	0.4	11
234	Fasting and cancer: molecular mechanisms and clinical application. <i>Nature Reviews Cancer</i> , 2018, 18, 707-719.	12.8	324
235	Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. <i>BMC Cancer</i> , 2018, 18, 982.	1.1	33
236	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	2.2	107
237	Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	102
238	The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. <i>Trends in Immunology</i> , 2018, 39, 900-920.	2.9	56
239	Potent immunosuppressive effects of the oncometabolite <i>α</i> -2-hydroxyglutarate. <i>OncImmunology</i> , 2018, 7, e1528815.	2.1	16
240	Pembrolizumab for the first-line treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1015-1021.	1.4	18
241	Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation. <i>Translational Oncology</i> , 2018, 11, 1323-1333.	1.7	74

#	ARTICLE	IF	CITATIONS
242	What a dog transmissible tumor can teach us about cancer regression. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1472059.	0.3	0
243	Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies. <i>Oncotarget</i> , 2018, 9, 31411-31421.	0.8	47
244	Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. <i>PLoS ONE</i> , 2018, 13, e0203070.	1.1	7
245	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 209-215.	2.0	29
246	Where does PD-1 blockade fit in HL therapy?. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 213-220.	0.9	9
247	Emerging biomarkers for immune checkpoint inhibition in lung cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 269-277.	4.3	67
248	Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. <i>Annals of Oncology</i> , 2018, 29, 1727-1740.	0.6	20
249	Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 258-273.	1.0	41
250	Doxorubicin Expands &in Vivo& Secretion of Circulating Exosome in Mice. <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 1078-1083.	0.6	13
251	Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect – a glimpse to the future. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 569-572.	1.9	4
252	Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5685-5696.	3.2	76
253	The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one. <i>Cancer Treatment Reviews</i> , 2018, 70, 41-46.	3.4	21
254	Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1786.	2.2	29
255	Personalized Cancer Immunotherapy via Transporting Endogenous Tumor Antigens to Lymph Nodes Mediated by Nano Fe <sub>3</sub> O <sub>4</sub> . <i>Small</i> , 2018, 14, e1801372.	5.2	30
256	Potentiating cancer vaccine efficacy in liver cancer. <i>Oncolmmunology</i> , 2018, 7, e1488564.	2.1	26
257	Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit. <i>Clinical Cancer Research</i> , 2018, 24, 5574-5584.	3.2	111
258	Melanoma treatment in review. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 35-49.	2.7	483
259	Modeling Tumor Immunology and Immunotherapy in Mice. <i>Trends in Cancer</i> , 2018, 4, 599-601.	3.8	63

#	ARTICLE	IF	CITATIONS
260	Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. <i>Frontiers in Immunology</i> , 2018, 9, 164.	2.2	103
261	Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 394.	2.2	84
262	Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. <i>Haematologica</i> , 2018, 103, 1256-1268.	1.7	69
263	Immune Landscape of Breast Cancers. <i>Biomedicines</i> , 2018, 6, 20.	1.4	81
264	Co-delivery of Doxorubicin and Interferon- $\beta$ by Thermosensitive Nanoparticles for Cancer Immunochemotherapy. <i>Molecular Pharmaceutics</i> , 2018, 15, 4161-4172.	2.3	51
265	Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer. <i>European Urology</i> , 2018, 74, 688-692.	0.9	28
266	Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 21-31.	1.1	32
267	Hyperthermic treatment at 56°C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens. <i>Vaccine</i> , 2018, 36, 3708-3716.	1.7	11
268	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. <i>Annual Review of Biomedical Data Science</i> , 2018, 1, 1-27.	2.8	27
269	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 1739.	2.2	174
270	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. <i>Lung Cancer</i> , 2018, 125, 273-281.	0.9	69
271	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. <i>Oncolmmunology</i> , 2018, 7, e1503032.	2.1	67
272	DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. <i>Anti-Cancer Drugs</i> , 2018, 29, 774-785.	0.7	12
273	Breast Cancer Immunotherapy: An Update. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341877480.	0.6	37
274	Immunogenic effects of chemotherapy-induced tumor cell death. <i>Genes and Diseases</i> , 2018, 5, 194-203.	1.5	219
275	Autophagy Inhibition and Chemosensitization in Cancer Therapy. , 2019, , 259-273.		3
276	Examination of the cellular mechanisms of leukocyte elevation by 10.6 $\mu$ m and 650nm laser acupuncture-moxibustion. <i>Lasers in Medical Science</i> , 2019, 34, 263-271.	1.0	8
277	Contribution of annexin A1 to anticancer immunosurveillance. <i>Oncolmmunology</i> , 2019, 8, e1647760.	2.1	27



#	ARTICLE	IF	CITATIONS
278	CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin. <i>International Journal of Cancer</i> , 2019, 145, 3112-3125.	2.3	32
279	The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 7175-7188.	3.2	90
280	Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2398-2405.	0.8	28
281	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2371-2383.	1.1	4
282	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. <i>Immunotherapy</i> , 2019, 11, 1149-1160.	1.0	9
283	NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 138, 105034.	1.9	16
284	The evolving landscape of immunotherapy in advanced prostate cancer. <i>Immunotherapy</i> , 2019, 11, 903-912.	1.0	22
285	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. <i>Nature Reviews Cancer</i> , 2019, 19, 420-438.	12.8	98
286	An immune infiltration signature to predict the overall survival of patients with colon cancer. <i>IUBMB Life</i> , 2019, 71, 1760-1770.	1.5	67
287	Identification and validation of an immune cell infiltrating score predicting survival in patients with lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 217.	1.8	57
288	The Nutritional Value and Biological Activity of Concentrated Protein Fraction of Potato Juice. <i>Nutrients</i> , 2019, 11, 1523.	1.7	62
289	Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy. <i>Nano Letters</i> , 2019, 19, 5356-5365.	4.5	87
290	NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. <i>Nature Communications</i> , 2019, 10, 3251.	5.8	55
291	Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. <i>Translational Oncology</i> , 2019, 12, 1314-1322.	1.7	46
292	Inhaled Submicron Particle Paclitaxel (NanoPac) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2019, 32, 266-277.	0.7	11
293	Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e452-e463.	5.1	150
294	<p>Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer</p>. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 47-56.	1.3	12
295	Immunotherapy in Ovarian Cancer. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 447-464.	0.6	27

#	ARTICLE	IF	CITATIONS
296	Durvalumab in cancer medicine: a comprehensive review. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 927-935.	1.4	36
297	Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. <i>Scientific Reports</i> , 2019, 9, 15099.	1.6	40
298	Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. <i>Cancer Immunology Research</i> , 2019, 7, 1958-1969.	1.6	87
299	Immunogenic cell death in a combined synergic gene- and immune-therapy against cancer. <i>Oncolmmunology</i> , 2019, 8, e1667743.	2.1	13
300	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 34.	2.3	55
301	Immunotherapy Against Gliomas: is the Breakthrough Near?. <i>Drugs</i> , 2019, 79, 1839-1848.	4.9	10
302	WNT/ $\beta$ -Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 2293.	2.2	165
303	Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression. <i>Aging Cell</i> , 2019, 18, e13027.	3.0	79
304	An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 789-792.	0.6	17
305	Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 1049.	1.3	24
306	Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 2067-2080.	2.0	34
307	The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 1162.	1.3	25
308	Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1270.	1.3	76
309	Tumor Immune Microenvironment and Chemosensitivity Signature for Predicting Response to Chemotherapy in Gastric Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 2065-2073.	1.6	78
310	Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 764.	3.8	720
311	Targeting Autophagy in Cancer: Recent Advances and Future Directions. <i>Cancer Discovery</i> , 2019, 9, 1167-1181.	7.7	579
312	Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2786-2794.	0.8	154
313	Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response. <i>Cancers</i> , 2019, 11, 1217.	1.7	36

#	ARTICLE	IF	CITATIONS
314	Transformable Nanoparticle-Enabled Synergistic Elicitation and Promotion of Immunogenic Cell Death for Triple-Negative Breast Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2019, 29, 1905213.	7.8	65
315	Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. <i>Oncotarget</i> , 2019, 8, e1655964.	2.1	97
316	Stress-glucocorticoid-TSC2/2D3 axis compromises therapy-induced antitumor immunity. <i>Nature Medicine</i> , 2019, 25, 1428-1441.	15.2	185
317	Next-generation computational tools for interrogating cancer immunity. <i>Nature Reviews Genetics</i> , 2019, 20, 724-746.	7.7	131
318	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncotarget</i> , 2019, 8, e1657375.	2.1	56
319	Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. <i>Molecular Cancer Research</i> , 2019, 17, 2395-2409.	1.5	36
320	Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses. <i>Frontiers in Immunology</i> , 2019, 10, 2121.	2.2	35
321	Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen. <i>Scientific Reports</i> , 2019, 9, 13471.	1.6	9
322	Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment. <i>Nano Letters</i> , 2019, 19, 8021-8031.	4.5	61
323	Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. <i>Radiographics</i> , 2019, 39, 1923-1937.	1.4	109
324	Immune control by amino acid catabolism during tumorigenesis and therapy. <i>Nature Reviews Cancer</i> , 2019, 19, 162-175.	12.8	170
325	Tumor Microenvironment-Triggered Aggregated Magnetic Nanoparticles for Reinforced Image-Guided Immunogenic Chemotherapy. <i>Advanced Science</i> , 2019, 6, 1802134.	5.6	90
326	Regulatory T cells in cancer immunosuppression implications for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 356-371.	12.5	872
327	Tumor Microenvironment Modulates Immunological Outcomes of Myeloid Cells with mTORC1 Disruption. <i>Journal of Immunology</i> , 2019, 202, 1623-1634.	0.4	8
328	Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 291-300.	2.0	14
329	Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 563-575.	2.0	22
330	Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. <i>Genome Medicine</i> , 2019, 11, 34.	3.6	732
331	Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches. <i>Advances in Cancer Research</i> , 2019, 144, 193-261.	1.9	19

#	ARTICLE	IF	CITATIONS
332	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. <i>Frontiers in Immunology</i> , 2019, 10, 1181.	2.2	20
333	Advances in cancer immunotherapy 2019 – latest trends. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 268.	3.5	401
334	Targeting the Tumor Microenvironment of Leukemia and Lymphoma. <i>Trends in Cancer</i> , 2019, 5, 351-364.	3.8	67
335	Type I interferons and dendritic cells in cancer immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2019, 348, 217-262.	1.6	81
336	Heat-activated drug delivery increases tumor accumulation of synergistic chemotherapies. <i>Journal of Controlled Release</i> , 2019, 308, 197-208.	4.8	42
337	Effect of Thermal Processing on Antioxidant Activity and Cytotoxicity of Waste Potato Juice. <i>Open Life Sciences</i> , 2019, 14, 150-157.	0.6	25
338	Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1897-1905.	1.2	4
339	Interferon- $\beta$ induces cancer cell ferroptosis. <i>Cell Research</i> , 2019, 29, 692-693.	5.7	28
340	Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 4023-4031.	1.3	44
341	Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines. <i>Cancer Letters</i> , 2019, 459, 192-203.	3.2	23
342	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. <i>Pharmacological Research</i> , 2019, 145, 104258.	3.1	115
343	Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. <i>Cancer Research</i> , 2019, 79, 3455-3465.	0.4	60
344	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 307-325.	12.8	879
345	My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11579-11586.	3.3	15
346	Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 178-189.	2.0	31
347	Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments. <i>Journal of Controlled Release</i> , 2019, 305, 130-154.	4.8	40
348	Cancer cells induce immune escape via glyocalyx changes controlled by the telomeric protein $\alpha$ -TRF. <i>EMBO Journal</i> , 2019, 38, .	3.5	49
349	CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1903.	1.8	15

#	ARTICLE	IF	CITATIONS
350	Crizotinib â€“ a tyrosine kinase inhibitor that stimulates immunogenic cell death. <i>Oncolimmunology</i> , 2019, 8, e1596652.	2.1	25
351	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. <i>Cancer Treatment Reviews</i> , 2019, 76, 22-32.	3.4	224
352	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. <i>Clinical Cancer Research</i> , 2019, 25, 5743-5751.	3.2	129
353	The Highs and Lows of Immune-Checkpoint Blockade in Lymphoma. <i>Cancer Immunology Research</i> , 2019, 7, 696-700.	1.6	14
354	Neddylation inhibition upregulates PDâ€“1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma. <i>International Journal of Cancer</i> , 2019, 145, 763-774.	2.3	33
355	Lymphopenia predicts response to stereotactic radiosurgery in lung cancer patients with brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 143, 337-347.	1.4	15
356	Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML. <i>Leukemia and Lymphoma</i> , 2019, 60, 2771-2778.	0.6	15
357	Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 67-81.	2.0	44
358	A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers. <i>Oncolimmunology</i> , 2019, 8, 1606665.	2.1	12
359	Optimal control of acute myeloid leukaemia. <i>Journal of Theoretical Biology</i> , 2019, 470, 30-42.	0.8	23
360	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune-Checkpoint Inhibitors. <i>BioDrugs</i> , 2019, 33, 159-171.	2.2	40
361	Chemoradiotherapy-Induced CD4+ and CD8+ T-Cell Alterations to Predict Patient Outcomes in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 73.	1.3	17
362	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	0.6	78
363	Efficacy of subsequent docetaxel +/â€“ ramucirumab and Sâ€“1 after nivolumab for patients with advanced nonâ€“small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1141-1148.	0.8	11
364	Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 1-6.	2.0	26
365	Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIOâ€“04 randomized phase 3 rectal cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 2282-2291.	2.3	21
366	<i>Orostachys japonicus</i> A. Berger Extracts Induce Immunity-Enhancing Effects on Cyclophosphamide-Treated Immunosuppressed Rats. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	7
367	Reply to L. Pala et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 439-440.	0.8	3

#	ARTICLE	IF	CITATIONS
368	Combining conventional therapy with immunotherapy: A risky business?. <i>European Journal of Cancer</i> , 2019, 113, 41-44.	1.3	25
369	Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. <i>Cancer Letters</i> , 2019, 454, 191-203.	3.2	60
370	Trial watch: dietary interventions for cancer therapy. <i>Oncoimmunology</i> , 2019, 8, e1591878.	2.1	52
371	T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. <i>Annals of Oncology</i> , 2019, 30, 934-944.	0.6	20
372	A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 195.	1.3	48
373	Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 602.	2.2	8
374	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 1486.	5.8	189
375	First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids <i>in vitro</i> . <i>Metallomics</i> , 2019, 11, 1044-1048.	1.0	92
376	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination. <i>European Journal of Medicinal Chemistry</i> , 2019, 171, 255-264.	2.6	11
377	Two Cu(II) coordination polymers based on benzene-1,3,5-tricarboxylate and 1,2,4-triazolide ligands: their crystal structures and application of nanoparticles in anti-esophageal cancer activity evaluation. <i>Structural Chemistry</i> , 2019, 30, 1485-1494.	1.0	2
378	cRGD target liposome delivery system promoted immunogenic cell death through enhanced anticancer potency of a thymidine conjugate under UVA activation as a cancer vaccine. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 499-509.	2.6	13
379	Harnessing the Immune System in HER2+ Disease. , 2019, , 213-230.		0
380	Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. <i>Nature Communications</i> , 2019, 10, 620.	5.8	60
381	Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review). <i>Oncology Letters</i> , 2019, 17, 2583-2591.	0.8	16
382	Maytansine-bearing antibody-drug conjugates induce <i>in vitro</i> hallmarks of immunogenic cell death selectively in antigen-positive target cells. <i>Oncoimmunology</i> , 2019, 8, e1565859.	2.1	31
383	Combined locoregional-immunotherapy for liver cancer. <i>Journal of Hepatology</i> , 2019, 70, 999-1007.	1.8	146
384	Turning the corner on therapeutic cancer vaccines. <i>Npj Vaccines</i> , 2019, 4, 7.	2.9	490
385	Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. <i>Medicinal Research Reviews</i> , 2019, 39, 1398-1426.	5.0	98

#	ARTICLE	IF	CITATIONS
386	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 396-416.	3.6	66
387	Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment. <i>Journal of Thoracic Disease</i> , 2019, 11, 35-38.	0.6	28
388	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2019, 11, 201.	1.7	49
389	Laser Ablation and Immune Stimulating Interstitial Laser Thermotherapy. , 2019, , .		0
390	Cancer Vaccines. , 2019, , .		1
391	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first- or second-line treatment of advanced gastric and gastro-esophageal junction cancer. <i>The Cochrane Library</i> , 0, , .	1.5	0
392	Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer. <i>Nano Today</i> , 2019, 29, 100801.	6.2	48
393	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2019, 629, xxi-xl.	0.4	1
394	Long Non-coding RNA LINC01787 Drives Breast Cancer Progression via Disrupting miR-125b Generation. <i>Frontiers in Oncology</i> , 2019, 9, 1140.	1.3	14
395	Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial. , 2019, 7, 318.		12
396	Temperature as a modulator of the gut microbiome: what are the implications and opportunities for thermal medicine?. <i>International Journal of Hyperthermia</i> , 2019, 36, 83-89.	1.1	31
397	Combination Immunotherapy Strategies in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 228-240.	0.5	5
398	Pharmacological plasticity" How do you hit a moving target?. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00532.	1.1	7
399	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
400	BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19 <sup>high</sup> B lymphocytes. , 2019, 7, 313.		67
401	An aminophosphonate ester ligand-containing platinum(II) complex induces potent immunogenic cell death <i>in vitro</i> and elicits effective anti-tumour immune responses <i>in vivo</i> . <i>Chemical Communications</i> , 2019, 55, 13066-13069.	2.2	50
402	Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 130, 89-96.	0.3	23
403	WNT Signaling in Cancer Immunosurveillance. <i>Trends in Cell Biology</i> , 2019, 29, 44-65.	3.6	168

#	ARTICLE	IF	CITATIONS
404	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2
405	Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency. <i>Cancer</i> , 2019, 125, 337-339.	2.0	0
406	Anticancer effects of anti-CD47 immunotherapy <i>in vivo</i> . <i>Oncolimmunology</i> , 2019, 8, 1550619.	2.1	32
407	Tumor endothelial cells as a potential target of metronomic chemotherapy. <i>Archives of Pharmacal Research</i> , 2019, 42, 1-13.	2.7	32
408	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 197-218.	21.5	2,005
409	The synthetic peptide LyeTxI-b derived from <i>Lycosa erythrognatha</i> spider venom is cytotoxic to U-87 MG glioblastoma cells. <i>Amino Acids</i> , 2019, 51, 433-449.	1.2	13
410	Doxorubicin-induced cardiotoxicity involves IFN $\gamma$ -mediated metabolic reprogramming in cardiomyocytes. <i>Journal of Pathology</i> , 2019, 247, 320-332.	2.1	36
411	Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 2219-2227.	3.2	32
412	Born to Kill: NK Cells Go to War against Cancer. <i>Trends in Cancer</i> , 2019, 5, 143-145.	3.8	2
413	Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 225-232.	1.4	22
414	Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma. <i>International Immunopharmacology</i> , 2019, 68, 131-136.	1.7	14
415	Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. <i>Oncolimmunology</i> , 2019, 8, e1539614.	2.1	17
416	Herbal Medicines as Adjuncts to Cancer Chemotherapy—Part 1: Immunomodulators. <i>Alternative and Complementary Therapies</i> , 2019, 25, 46-52.	0.1	2
417	A low protein diet to target cardiovascular disease and cancer in one shot?. <i>Cardiovascular Research</i> , 2019, 115, e1-e2.	1.8	0
418	Low Molecular Weight Heparin-Coated and Dendrimer-Based Core-Shell Nanoplatform with Enhanced Immune Activation and Multiple Anti-Metastatic Effects for Melanoma Treatment. <i>Theranostics</i> , 2019, 9, 337-354.	4.6	46
419	Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 29-42.	1.1	11
420	Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health. <i>Pharmacological Reviews</i> , 2019, 71, 1-19.	7.1	47
421	Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. <i>Oncogene</i> , 2019, 38, 2814-2829.	2.6	85



#	ARTICLE	IF	CITATIONS
422	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	23.0	237
423	T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. <i>Haematologica</i> , 2019, 104, 338-346.	1.7	38
424	Can Haematology Blood Tests at Time of Diagnosis Predict Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer?. <i>Digestive Surgery</i> , 2019, 36, 495-501.	0.6	7
425	Pathophysiology of Cancer Cell Death. , 2020, , 74-83.e4.		2
426	Oncolysis without viruses â€” inducing systemic anticancer immune responses with local therapies. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 49-64.	12.5	92
427	Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence. <i>British Journal of Pharmacology</i> , 2020, 177, 1409-1423.	2.7	217
428	Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq. <i>Methods in Enzymology</i> , 2020, 636, 261-285.	0.4	141
429	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2020, 16, 4439-4453.	1.1	29
430	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients. <i>Immunological Medicine</i> , 2020, 43, 10-15.	1.4	3
431	Novel immunotherapy combinations for genitourinary cancers. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 253-262.	1.4	11
432	Antitumour immunity invoked by hepatic arterial infusion of firstâ€”line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8â€”12â€”years of followâ€”up. <i>International Journal of Cancer</i> , 2020, 146, 2019-2026.	2.3	14
433	Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade. <i>Journal of Immunotherapy</i> , 2020, 43, 57-66.	1.2	36
434	Immunostimulatory effects of polysaccharides isolated from young barley leaves ( <i>Hordeum vulgare</i> ) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 immunosuppressed mice. <i>International Journal of Biological Macromolecules</i> , 2020, 147, 954-964.	3.6	26
435	Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 383-397.	2.0	17
436	Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 1763-1772.	3.2	64
437	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. <i>Cellular and Molecular Immunology</i> , 2020, 17, 13-26.	4.8	76
438	Restoration and Enhancement of Immunogenic Cell Death of Cisplatin by Coadministration with Digoxin and Conjugation to HPMA Copolymer. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 1606-1616.	4.0	30
439	Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6Chigh Myeloid Cells. <i>Journal of Immunology</i> , 2020, 204, 212-223.	0.4	42

#	ARTICLE	IF	CITATIONS
440	DNA Damage Response and Oxidative Stress in Systemic Autoimmunity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 55.	1.8	68
441	Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2020, 49, 1240-1245.	0.5	4
442	Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 587460.	2.2	87
443	Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6838.	1.8	21
444	Splenic Hematopoietic and Stromal Cells in Cancer Progression. <i>Cancer Research</i> , 2021, 81, 27-34.	0.4	19
445	Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. <i>Chinese Medical Journal</i> , 2020, 133, 2444-2455.	0.9	7
446	The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature. <i>Current Treatment Options in Oncology</i> , 2020, 21, 95.	1.3	15
447	New insights into the activities and toxicities of the old anticancer drug doxorubicin. <i>FEBS Journal</i> , 2021, 288, 6095-6111.	2.2	149
448	The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer. <i>Cancers</i> , 2020, 12, 2872.	1.7	12
449	Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2020, 160, 19-35.	6.6	27
450	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. <i>Oral Oncology</i> , 2020, 109, 104977.	0.8	10
451	PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy. <i>Scientific Reports</i> , 2020, 10, 16150.	1.6	2
452	Developing a holistic contingency plan: Challenges and dilemmas for cancer patients during the COVID-19. <i>Cancer Medicine</i> , 2020, 9, 6082-6092.	1.3	9
453	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. <i>Melanoma Research</i> , 2020, 30, 364-375.	0.6	42
454	Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110504.	2.5	26
455	Trial watch: STING agonists in cancer therapy. <i>Oncolimmunology</i> , 2020, 9, 1777624.	2.1	148
456	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2120-2136.	1.3	16
457	Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?. <i>ESMO Open</i> , 2020, 5, e001112.	2.0	30

#	ARTICLE	IF	CITATIONS
458	A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2082-2096.	1.3	4
459	Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1193-1193.	0.7	25
460	Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review. <i>BMJ Open</i> , 2020, 10, e034010.	0.8	6
461	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 236.	3.5	44
462	Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. <i>Nature Communications</i> , 2020, 11, 6175.	5.8	92
463	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2021, 7, 1092-1099.	1.6	4
464	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
465	IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T-Lymphocyte Subpopulations in Patients Treated for Lung Adenocarcinoma. <i>Biology</i> , 2020, 9, 376.	1.3	15
466	Synthesis, In Silico Prediction and In Vitro Evaluation of Antitumor Activities of Novel Pyrido[2,3-d]pyrimidine, Xanthine and Lumazine Derivatives. <i>Molecules</i> , 2020, 25, 5205.	1.7	18
467	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 725-741.	12.5	701
468	Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2020, 10, 13078.	1.6	17
469	Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. <i>Onc Immunology</i> , 2020, 9, 1795995.	2.1	29
470	Polymer nanomedicines. <i>Advanced Drug Delivery Reviews</i> , 2020, 156, 40-64.	6.6	66
471	Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 immunotherapy. <i>Theranostics</i> , 2020, 10, 8382-8399.	4.6	42
472	Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience. <i>Oncology Research</i> , 2020, 28, 237-248.	0.6	8
473	Penetrable Nanoplatfor for Cold Tumor Immune Microenvironment Reeducation. <i>Advanced Science</i> , 2020, 7, 2000411.	5.6	53
474	Photocontrolled activation of small molecule cancer therapeutics. <i>RSC Medicinal Chemistry</i> , 2020, 11, 982-1002.	1.7	18
475	PlatinER: A Highly Potent Anticancer Platinum(II) Complex that Induces Endoplasmic Reticulum Stress Driven Immunogenic Cell Death. <i>Angewandte Chemie</i> , 2020, 132, 19232-19240.	1.6	13

#	ARTICLE	IF	CITATIONS
476	A brief report on combination chemotherapy and anti-“programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?. <i>European Journal of Cancer</i> , 2020, 137, 40-44.	1.3	5
477	Translational Nanomedicine Boosts Anti-PD1 Therapy to Eradicate Orthotopic PTEN-Negative Glioblastoma. <i>ACS Nano</i> , 2020, 14, 10127-10140.	7.3	47
478	PlatinER: A Highly Potent Anticancer Platinum(II) Complex that Induces Endoplasmic Reticulum Stress Driven Immunogenic Cell Death. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 19070-19078.	7.2	79
479	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. <i>Lung Cancer</i> , 2020, 147, 259-268.	0.9	31
480	Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 421-431.	1.1	9
481	Mechanisms of Cancer Resistance to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1290.	1.3	159
482	Improvements in the Oral Absorption and Anticancer Efficacy of an Oxaliplatin-Loaded Solid Formulation: Pharmacokinetic Properties in Rats and Nonhuman Primates and the Effects of Oral Metronomic Dosing on Colorectal Cancer. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 7719-7743.	3.3	12
483	Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma. <i>Cancers</i> , 2020, 12, 3153.	1.7	15
484	Antitumor, Immunomodulatory and Antiangiogenic Efficacy of Medicinal Mushroom Extract Mixtures in Advanced Colorectal Cancer Animal Model. <i>Molecules</i> , 2020, 25, 5005.	1.7	16
485	In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. , 2020, 8, e001071.		24
486	Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated “ NIVACOR trial (GOIRC-03-2018). <i>BMC Cancer</i> , 2020, 20, 822.	1.1	13
487	LINC00973 is involved in cancer immune suppression through positive regulation of Siglec15 in clear-cell renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 3693-3704.	1.7	28
488	Metabolic programming of tumor associated macrophages in the context of cancer treatment. <i>Annals of Translational Medicine</i> , 2020, 8, 1028-1028.	0.7	16
489	Prognostic and Predictive Value of an Immunoscore Signature in Glioblastoma Multiform. <i>Frontiers in Genetics</i> , 2020, 11, 514363.	1.1	8
490	A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6802.	1.8	5
491	Overcoming resistance to immunotherapy by teaching old drugs new tricks. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1801088.	0.3	1
492	Thymic Engraftment by in vitro-Derived Progenitor T Cells in Young and Aged Mice. <i>Frontiers in Immunology</i> , 2020, 11, 1850.	2.2	9
493	Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy. <i>Cancer Medicine</i> , 2020, 9, 8432-8443.	1.3	4

#	ARTICLE	IF	CITATIONS
494	Tackling Resistance to Cancer Immunotherapy: What Do We Know?. <i>Molecules</i> , 2020, 25, 4096.	1.7	12
495	PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. <i>Nature Cell Biology</i> , 2020, 22, 1264-1275.	4.6	508
496	Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. <i>Blood Advances</i> , 2020, 4, 4256-4266.	2.5	12
498	Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions. <i>Current Opinion in Oncology</i> , 2020, 32, 434-441.	1.1	3
499	Cross-reactivity between tumor MHC class II-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942.	6.0	217
500	Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	1.4	24
501	An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer. <i>Nature Communications</i> , 2020, 11, 6352.	5.8	67
502	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. <i>Npj Precision Oncology</i> , 2020, 4, 29.	2.3	11
503	What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?. <i>Cancer Journal (Sudbury, Mass.)</i> , 2020, 26, 485-495.	1.0	5
504	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. <i>Cancers</i> , 2020, 12, 3173.	1.7	36
505	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2020, 11, 598877.	2.2	133
506	Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma. , 2020, 8, e000807.		29
507	An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. <i>Theranostics</i> , 2020, 10, 11938-11949.	4.6	85
508	Protein Kinase A Catalytic Subunit Is a Molecular Switch that Promotes the Pro-tumoral Function of Macrophages. <i>Cell Reports</i> , 2020, 31, 107643.	2.9	16
509	FOLFOLX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 586.	1.3	42
510	Novel Forms of Immunomodulation for Cancer Therapy. <i>Trends in Cancer</i> , 2020, 6, 518-532.	3.8	17
511	Warburg and Beyond: The Power of Mitochondrial Metabolism to Collaborate or Replace Fermentative Glycolysis in Cancer. <i>Cancers</i> , 2020, 12, 1119.	1.7	117
512	Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy. <i>Science Advances</i> , 2020, 6, eaaz9240.	4.7	119

#	ARTICLE	IF	CITATIONS
513	Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells. <i>Cancers</i> , 2020, 12, 1314.	1.7	13
514	Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. , 2020, 8, e000367.		72
515	Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go. <i>Current Treatment Options in Oncology</i> , 2020, 21, 59.	1.3	12
516	Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 482-491.	0.4	8
517	Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 4542-4550.	3.2	65
518	Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 777.	1.3	6
519	Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program. <i>BMC Immunology</i> , 2020, 21, 12.	0.9	5
520	Biomaterial-based strategies to prime dendritic cell-mediated anti-cancer immune responses. <i>International Materials Reviews</i> , 2020, 65, 445-462.	9.4	16
521	Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis. <i>Gastric Cancer</i> , 2020, 23, 648-658.	2.7	7
522	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
523	<p>Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1339-1346.	0.9	12
524	Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity. <i>Seminars in Cancer Biology</i> , 2022, 79, 68-82.	4.3	15
525	Cancer Immunotherapy with CDK7 Inhibitors. <i>Trends in Cancer</i> , 2020, 6, 361-363.	3.8	1
526	Gender Disparity Impacts on Thymus Aging and LHRH Receptor Antagonist-Induced Thymic Reconstitution Following Chemotherapeutic Damage. <i>Frontiers in Immunology</i> , 2020, 11, 302.	2.2	17
527	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
528	Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1391-1401.	2.0	10
529	Liver Transplantation for Pediatric Liver Cancer. <i>Cancers</i> , 2020, 12, 720.	1.7	22
530	Immunogenic cell death in colon cancer prevention and therapy. <i>Molecular Carcinogenesis</i> , 2020, 59, 783-793.	1.3	65

#	ARTICLE	IF	CITATIONS
531	Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. <i>Nature Immunology</i> , 2020, 21, 546-554.	7.0	78
532	The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. <i>BioDrugs</i> , 2020, 34, 349-362.	2.2	33
533	Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models. <i>Cancers</i> , 2020, 12, 636.	1.7	40
534	The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 233-242.	1.0	7
535	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 223.	2.2	54
536	The link between Cancer and autoimmune diseases in the light of microbiota: Evidence of a potential culprit. <i>Immunology Letters</i> , 2020, 222, 12-28.	1.1	14
537	Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. <i>Oncolmmunology</i> , 2020, 9, 1748982.	2.1	23
538	Keeping Patients With Cancer Exercising in the Age of COVID-19. <i>JCO Oncology Practice</i> , 2020, 16, 656-664.	1.4	55
539	Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4493.	1.8	7
540	Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. <i>Oncolmmunology</i> , 2020, 9, 1789284.	2.1	4
541	Fluoropyrimidine Modulation of the Anti-Tumor Immune Response—Prospects for Improved Colorectal Cancer Treatment. <i>Cancers</i> , 2020, 12, 1641.	1.7	22
542	Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 462.	1.7	57
543	The abscopal effect 67 years later: from a side story to center stage. <i>British Journal of Radiology</i> , 2020, 93, 20200042.	1.0	73
544	The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 11-17.	1.8	64
545	Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 745-758.	2.0	27
546	Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. <i>Annals of Oncology</i> , 2020, 31, 569-581.	0.6	253
547	Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 124.	1.1	8
548	Intratumoral Immunotherapy for Early-stage Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 3091-3099.	3.2	88

#	ARTICLE	IF	CITATIONS
549	A Calreticulin Tail: C-terminal Mutants of Calreticulin Allow Cancer Cells to Evade Phagocytosis. <i>Molecular Cell</i> , 2020, 77, 683-685.	4.5	5
550	Harnessing cancer immunotherapy during the unexploited immediate perioperative period. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 313-326.	12.5	60
551	Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1612.	3.3	33
552	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1
553	A prophylactic and a therapeutic against AML. <i>Nature Biomedical Engineering</i> , 2020, 4, 4-5.	11.6	2
554	PD-1/PD-L1-dependent immune response in colorectal cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 5461-5475.	2.0	86
555	Dose and therapy individualization in cancer chemotherapy. <i>Handbook of Analytical Separations</i> , 2020, , 291-319.	0.8	4
556	Photodynamic therapy mediated by aluminium-phthalocyanine nanoemulsion eliminates primary tumors and pulmonary metastases in a murine 4T1 breast adenocarcinoma model. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2020, 204, 111808.	1.7	22
557	Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy. <i>Journal of Translational Medicine</i> , 2020, 18, 34.	1.8	10
558	Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy <i>in vivo</i> . <i>Drug Delivery</i> , 2020, 27, 180-190.	2.5	55
559	Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. <i>Oncolimmunology</i> , 2020, 9, 1677427.	2.1	8
560	Tumor Immunology and Tumor Evolution: Intertwined Histories. <i>Immunity</i> , 2020, 52, 55-81.	6.6	357
561	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. <i>Oncolimmunology</i> , 2020, 9, 1703449.	2.1	156
562	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
563	Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2444-2451.	3.2	94
564	5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 492.	1.3	33
565	Metal-Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications. <i>Nano-Micro Letters</i> , 2020, 12, 103.	14.4	363
566	Breast cancer: Biology, biomarkers, and treatments. <i>International Immunopharmacology</i> , 2020, 84, 106535.	1.7	307



#	ARTICLE	IF	CITATIONS
567	Design principles of drug combinations for chemotherapy. <i>Journal of Controlled Release</i> , 2020, 323, 36-46.	4.8	33
568	Dendritic cell therapy in cancer treatment; the state-of-the-art. <i>Life Sciences</i> , 2020, 254, 117580.	2.0	91
569	“Watson-Crick” inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy. <i>Journal of Materials Chemistry B</i> , 2020, 8, 3829-3841.	2.9	7
570	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
571	Sequential Interferon $\gamma$ -Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner. <i>Biomolecules</i> , 2020, 10, 643.	1.8	20
572	Novel anti-EGFR scFv human antibody-conjugated immunoliposomes enhance chemotherapeutic efficacy in squamous cell carcinoma of head and neck. <i>Oral Oncology</i> , 2020, 106, 104689.	0.8	18
573	Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. <i>BMC Cancer</i> , 2020, 20, 352.	1.1	24
574	Prodrug-Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death. <i>Small</i> , 2020, 16, e2000214.	5.2	73
575	Dissecting the Tumor “Immune Landscape” in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. <i>Clinical Cancer Research</i> , 2020, 26, 3505-3513.	3.2	18
577	Characterization of CD103+ CD8+ tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1493-1504.	2.0	35
578	Artificial Nanoscale Erythrocytes from Clinically Relevant Compounds for Enhancing Cancer Immunotherapy. <i>Nano-Micro Letters</i> , 2020, 12, 90.	14.4	12
579	Overcoming Wnt $\beta$ -catenin dependent anticancer therapy resistance in leukaemia stem cells. <i>Nature Cell Biology</i> , 2020, 22, 689-700.	4.6	89
580	Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. <i>Blood</i> , 2020, 135, 597-609.	0.6	134
581	T-cell-based breast cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2021, 72, 90-101.	4.3	21
582	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 182-191.	3.0	49
583	Chemotherapy brings virtual memory T cells into reality for cancer therapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1339-1340.	4.8	0
584	Biomarkers for predicting the outcome of various cancer immunotherapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103161.	2.0	10
585	The T-Cell-Inflammation Status Can Predict Outcomes of Adjuvant Chemotherapy in Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1407-1416.	0.7	4

#	ARTICLE	IF	CITATIONS
586	Calreticulin and cancer. <i>Cell Research</i> , 2021, 31, 5-16.	5.7	174
587	Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 323-336.	2.0	25
588	IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment. <i>Biomaterials</i> , 2021, 269, 120388.	5.7	37
589	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. <i>British Journal of Cancer</i> , 2021, 124, 414-424.	2.9	38
590	<sup>18</sup> F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 802-807.	2.8	15
591	Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. <i>Medical Hypotheses</i> , 2021, 146, 110365.	0.8	24
592	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1267-1277.	3.2	21
593	Cyclophosphamide and Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 685-697.	0.4	31
594	Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 7.	1.3	6
595	An ER $\alpha$ -targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non-Small Cell Lung Cancer. <i>Angewandte Chemie</i> , 2021, 133, 4707-4715.	1.6	28
596	An ER $\alpha$ -targeting Iridium(III) Complex That Induces Immunogenic Cell Death in Non-Small Cell Lung Cancer. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 4657-4665.	7.2	144
597	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. <i>Journal of the National Cancer Institute</i> , 2021, 113, 513-522.	3.0	13
598	Immunotherapy for early breast cancer: too soon, too superficial, or just right?. <i>Annals of Oncology</i> , 2021, 32, 323-336.	0.6	79
599	Considerations for designing preclinical cancer immune nanomedicine studies. <i>Nature Nanotechnology</i> , 2021, 16, 6-15.	15.6	77
600	Role of miRNAs in regulating responses to radiotherapy in human breast cancer. <i>International Journal of Radiation Biology</i> , 2021, 97, 289-301.	1.0	9
601	Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy. <i>Biomaterials</i> , 2021, 269, 120604.	5.7	41
602	Immunomodulation by targeted anticancer agents. <i>Cancer Cell</i> , 2021, 39, 310-345.	7.7	131
603	Anticancer and antimicrobial peptides from medicinal plants of Borneo island in Sarawak. <i>Advances in Traditional Medicine</i> , 2021, 21, 189-197.	1.0	4

#	ARTICLE	IF	CITATIONS
604	The rediscovery of platinum-based cancer therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 37-50.	12.8	452
605	An update on the use of immunotherapy in patients with colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 291-304.	1.4	18
606	Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 519-531.	2.0	22
607	The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. <i>Seminars in Cancer Biology</i> , 2021, 72, 76-89.	4.3	87
608	Research advances and new challenges in overcoming triple-negative breast cancer. , 2021, 4, 517-542.		11
609	Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110185.	1.4	12
610	Targeting tumor resistance mechanisms. <i>Faculty Reviews</i> , 2021, 10, 6.	1.7	0
611	Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma. <i>Oncotarget</i> , 2021, 12, 66-80.	0.8	3
612	Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110011.	1.4	5
613	High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 87-99.	0.4	2
614	Calreticulin Exposure in Mitotic Catastrophe. <i>Methods in Molecular Biology</i> , 2021, 2267, 207-215.	0.4	1
615	Tumor-associated myeloid cells: diversity and therapeutic targeting. <i>Cellular and Molecular Immunology</i> , 2021, 18, 566-578.	4.8	100
616	Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. <i>Cancer Research</i> , 2021, 81, 3079-3091.	0.4	27
617	Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers. <i>Frontiers in Immunology</i> , 2020, 11, 607416.	2.2	2
618	Immunogenicity and cytotoxicity of a platinum(IV) complex derived from capsaicin. <i>Dalton Transactions</i> , 2021, 50, 3516-3522.	1.6	23
619	SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected and Non-Injected Lesions. <i>Advanced Therapeutics</i> , 2021, 4, 2000243.	1.6	31
620	Dynamic Monitoring of Immunotherapy Effectiveness with Different Biomarkers in the Patients with Non-Small Cell Lung Cancer. <i>Oncologie</i> , 2021, 23, 335-350.	0.2	1
621	Effective management of advanced colon cancer genotyping microsatellite stable/microsatellite instable-low with Kirsten rat sarcoma viral oncogene mutation using nivolumab plus ipilimumab combined with regorafenib and irinotecan: A case report. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110277.	0.2	1

#	ARTICLE	IF	CITATIONS
622	Auswirkungen von Chemotherapeutika auf zirkulierende Leukozytenpopulationen: Mögliche Implikationen für den Erfolg von CAR-T-Zell-Therapien. <i>Karger Kompass Onkologie</i> , 2021, 8, 116-127.	0.0	0
623	Metal-organic frameworks towards bio-medical applications. <i>Materials Chemistry Frontiers</i> , 2021, 5, 5573-5594.	3.2	39
624	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0
625	The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35
626	Combination Chemotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. <i>Advanced Science</i> , 2021, 8, 2002147.	5.6	59
627	Immuno-Oncology in Pancreatic Cancer. , 2021, , 287-304.		2
628	Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemotherapy. <i>Nanoscale</i> , 2021, 13, 17218-17235.	2.8	63
629	Complete response of metastatic cervical adenocarcinoma treated with chemoradiotherapy followed by pembrolizumab: A case report. <i>Journal of Case Reports and Images in Oncology</i> , 2021, 7, 1.	0.0	0
630	Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons. <i>Methods in Cell Biology</i> , 2021, 163, xvii-xxv.	0.5	0
631	Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 221-232.	1.3	7
632	Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression. , 2021, 9, e001636.		21
633	Role of Methylation in Pro- and Anti-Cancer Immunity. <i>Cancers</i> , 2021, 13, 545.	1.7	53
634	PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade. <i>European Journal of Cancer</i> , 2021, 144, 317-325.	1.3	13
635	An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 621623.	2.2	7
636	Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor. <i>Clinical and Translational Oncology</i> , 2021, 23, 1646-1656.	1.2	9
637	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2021, 11, 1524-1541.	7.7	103
638	nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+). <i>Frontiers in Oncology</i> , 2020, 10, 569715.	1.3	3
639	Non-invasive transdermal delivery of chemotherapeutic molecules in vivo using superparamagnetic iron oxide nanoparticles. <i>Cancer Nanotechnology</i> , 2021, 12, .	1.9	17

#	ARTICLE	IF	CITATIONS
640	5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer cell-intrinsic STING. <i>EMBO Journal</i> , 2021, 40, e106065.	3.5	44
641	Determinants of Health and Physical Activity Levels Among Breast Cancer Survivors During the COVID-19 Pandemic: A Cross-Sectional Study. <i>Frontiers in Physiology</i> , 2021, 12, 624169.	1.3	13
642	Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting. <i>Cancers</i> , 2021, 13, 670.	1.7	79
643	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	7.1	191
644	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. <i>Molecular Cancer</i> , 2021, 20, 27.	7.9	54
645	SIRT1 and gynecological malignancies (Review). <i>Oncology Reports</i> , 2021, 45, .	1.2	10
646	Depression and anxiety in cancer patients before and during the SARS-CoV-2 pandemic: association with treatment delays. <i>Quality of Life Research</i> , 2021, 30, 1903-1912.	1.5	34
647	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. <i>Cancers</i> , 2021, 13, 1300.	1.7	10
648	Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2021, 74, 625-634.	1.0	18
649	Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002104.	3.9	47
650	Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison. <i>Annals of Palliative Medicine</i> , 2021, 10, 2766-2775.	0.5	8
651	The Controlling Nutritional Status (CONUT) Score is a Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with First-Line Platinum-Based Chemotherapy. <i>Bladder Cancer</i> , 2021, 7, 13-21.	0.2	2
652	The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. <i>Leukemia</i> , 2021, 35, 2635-2649.	3.3	32
653	In vitro naphthylquinoxaline thymidine conjugate and UVA treated cancer cells are effective therapeutic vaccines for tumors in vivo with CpG as the adjuvant. <i>Journal of Advanced Research</i> , 2021, 35, 259-266.	4.4	1
654	Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients. <i>JCI Insight</i> , 2021, 6, .	2.3	14
655	Aldose reductase regulates doxorubicin-induced immune and inflammatory responses by activating mitochondrial biogenesis. <i>European Journal of Pharmacology</i> , 2021, 895, 173884.	1.7	7
656	Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity. <i>Frontiers in Oncology</i> , 2021, 11, 644608.	1.3	19
657	Underlying mechanisms and drug intervention strategies for the tumour microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 97.	3.5	22

#	ARTICLE	IF	CITATIONS
658	Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo-immunotherapy. <i>Small</i> , 2021, 17, e2005993.	5.2	35
659	Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3272-3285.	5.7	26
660	High-density lipoprotein modulates tumor-associated macrophage for chemoimmunotherapy of hepatocellular carcinoma. <i>Nano Today</i> , 2021, 37, 101064.	6.2	20
661	Colorectal Cancer and Immunity: From the Wet Lab to Individuals. <i>Cancers</i> , 2021, 13, 1713.	1.7	1
662	Prognostic role of proliferating CD8+ cytotoxic T cells in human cancers. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 793-803.	2.1	29
663	Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 665-681.	1.6	31
664	Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy. <i>Nature Communications</i> , 2021, 12, 2425.	5.8	75
665	Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. <i>Cellular Immunology</i> , 2021, 362, 104301.	1.4	12
666	Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. <i>Cancers</i> , 2021, 13, 2040.	1.7	4
667	Safety considerations with new treatment regimens for anal cancer. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 889-902.	1.0	2
669	Design, Synthesis and Anticancer Activity of New Polycyclic: Imidazole, Thiazine, Oxathione, Pyrrolo-Quinoxaline and Thienotriazolopyrimidine Derivatives. <i>Molecules</i> , 2021, 26, 2031.	1.7	20
670	Advances in Cancer Treatment by Targeting the Neddylation Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 653882.	1.8	27
671	Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds. <i>Oncogenesis</i> , 2021, 10, 33.	2.1	13
672	Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 131-147.	1.0	5
673	The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer. <i>Nature Cancer</i> , 2021, 2, 457-473.	5.7	31
674	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. <i>Blood Cancer Discovery</i> , 2021, 2, 468-483.	2.6	64
675	Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. <i>Cancers</i> , 2021, 13, 2225.	1.7	21
676	Challenges and Opportunities for Immunotherapy in Gynecologic Cancer. <i>Advances in Oncology</i> , 2021, 1, 113-123.	0.1	0

#	ARTICLE	IF	CITATIONS
677	Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. <i>Frontiers in Oncology</i> , 2021, 11, 559161.	1.3	34
678	Immune Checkpoint Inhibitors in Prostate Cancer. <i>Cancers</i> , 2021, 13, 2187.	1.7	48
679	Preparation and Performance of Chemotherapy Drug-Loaded Graphene Oxide-Based Nanosheets That Target Ovarian Cancer Cells via Folate Receptor Mediation. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 960-970.	0.5	5
680	Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 415-424.	0.4	6
681	Supramolecular Tadalafil Nanovaccine for Cancer Immunotherapy by Alleviating Myeloid-Derived Suppressor Cells and Heightening Immunogenicity. <i>Small Methods</i> , 2021, 5, e2100115.	4.6	44
682	Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 45-55.	2.0	39
683	Gene expression profiles for an immunoscore model in bone and soft tissue sarcoma. <i>Aging</i> , 2021, 13, 13708-13725.	1.4	7
684	Correlation between circulating blood and microenvironment T lymphocytes in diffuse large B-cell lymphomas. <i>Journal of Clinical Pathology</i> , 2022, 75, 493-497.	1.0	10
685	Immunogenic Cell Death-Based Cancer Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 697964.	2.2	51
686	Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. <i>Frontiers in Oncology</i> , 2021, 11, 635007.	1.3	76
687	Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 155, 144-150.	0.9	9
688	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 650486.	2.2	26
689	Multifaceted modes of action of the anticancer probiotic <i>Enterococcus hirae</i> . <i>Cell Death and Differentiation</i> , 2021, 28, 2276-2295.	5.0	18
690	Type of chemotherapy has substantial effects on the immune system in ovarian cancer. <i>Translational Oncology</i> , 2021, 14, 101076.	1.7	11
691	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 97, 102187.	3.4	31
692	Immunotherapy retreatment: case report, review of the literature and proposal for the definition of different scenarios. <i>Immunotherapy</i> , 2021, 13, 645-652.	1.0	2
693	Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 682261.	1.8	4
694	Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2475-2486.	1.3	13

#	ARTICLE	IF	CITATIONS
695	Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. <i>Nature Medicine</i> , 2021, 27, 1012-1024.	15.2	109
696	Humoral Immune Response of SARS-CoV-2-Infected Patients with Cancer: Influencing Factors and Mechanisms. <i>Oncologist</i> , 2021, 26, e1619-e1632.	1.9	16
697	Sphingosine Kinase Inhibition Enhances Dimerization of Calreticulin at the Cell Surface in Mitoxantrone-Induced Immunogenic Cell Death. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 300-310.	1.3	7
698	Methionine enkephalin activates autophagy and stimulates tumour cell immunogenicity in human cutaneous squamous cell carcinoma. <i>International Immunopharmacology</i> , 2021, 96, 107733.	1.7	7
699	Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. , 2021, 9, e002256.		18
700	Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 1128-1144.	0.8	10
701	Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. <i>Cell Death and Disease</i> , 2021, 12, 713.	2.7	29
702	Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 702642.	1.3	21
703	Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. <i>Communications Biology</i> , 2021, 4, 859.	2.0	13
704	Future prospects for mitosis-targeted antitumor therapies. <i>Biochemical Pharmacology</i> , 2021, 190, 114655.	2.0	24
705	Autophagy in major human diseases. <i>EMBO Journal</i> , 2021, 40, e108863.	3.5	615
706	IFN $\gamma$ signaling integrity in colorectal cancer immunity and immunotherapy. <i>Cellular and Molecular Immunology</i> , 2022, 19, 23-32.	4.8	57
707	First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. <i>Annals of Oncology</i> , 2021, 32, 983-993.	0.6	205
708	Tumor Microenvironment in Breast Cancer – Updates on Therapeutic Implications and Pathologic Assessment. <i>Cancers</i> , 2021, 13, 4233.	1.7	72
709	Evaluating prognostic value and relevant gene signatures of tumor microenvironment characterization in esophageal carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1228-1240.	0.6	4
710	Chemotherapy: a double-edged sword in cancer treatment. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 507-526.	2.0	91
711	Present and Future Research on Anal Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3895.	1.7	12
712	MCP-1-Functionalized, Core-Shell Gold Nanorod@Iron-Based Metal-Organic Framework (MCP-1/GNR@MIL-100(Fe)) for Photothermal Therapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 52092-52105.	4.0	15



#	ARTICLE	IF	CITATIONS
713	Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 651634.	2.2	47
714	Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy. <i>Pharmaceutics</i> , 2021, 13, 1387.	2.0	18
715	The Impact of COVID-19 on Cancer. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 3809-3816.	1.1	18
716	The effect of patient sex on the efficacy and safety of anticancer immunotherapy. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1535-1544.	1.0	10
717	Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. <i>Lung Cancer</i> , 2021, 159, 18-26.	0.9	46
718	LyeTx I-b Peptide Attenuates Tumor Burden and Metastasis in a Mouse 4T1 Breast Cancer Model. <i>Antibiotics</i> , 2021, 10, 1136.	1.5	6
719	Adcitmer <sup>®</sup> , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma*. <i>British Journal of Dermatology</i> , 2022, 186, 295-306.	1.4	9
720	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
721	Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients. <i>International Journal of Cancer</i> , 2022, 150, 636-644.	2.3	20
722	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202
723	Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1275-1289.	5.1	118
724	Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6761-6771.	3.2	33
725	Chemotherapy-induced autoimmune-mediated encephalitis during germinoma treatment. <i>Brain and Development</i> , 2021, 43, 967-971.	0.6	3
726	Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors. <i>Advanced Drug Delivery Reviews</i> , 2021, 177, 113927.	6.6	34
727	Macrophage polarization synergizes with oxaliplatin in lung cancer immunotherapy via enhanced tumor cell phagocytosis. <i>Translational Oncology</i> , 2021, 14, 101202.	1.7	10
728	Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms. <i>Translational Oncology</i> , 2021, 14, 101224.	1.7	2
729	Cyclophosphamide abrogates the expansion of CD4 <sup>+</sup> Foxp3 <sup>+</sup> regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	4
730	Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry. <i>Oncolmmunology</i> , 2021, 10, 1954761.	2.1	28

#	ARTICLE	IF	CITATIONS
731	IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110365.	1.4	24
732	Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 709-717.	1.3	14
733	Methods to Detect Immunogenic Cell Death In Vivo. <i>Methods in Molecular Biology</i> , 2020, 2055, 433-452.	0.4	5
734	Immunotherapy in Gastrointestinal Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 93-106.	0.8	7
735	Vaccine Approaches in Hepatocellular Carcinoma. , 2017, , 1-17.		1
736	Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 33-59.	0.8	232
737	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020, 38, 629-646.	7.7	196
738	Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response. <i>EBioMedicine</i> , 2021, 64, 103160.	2.7	13
739	Opportunities for Small Molecules in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2020, 41, 493-511.	2.9	82
740	Gd-metallofullerenol drug delivery system mediated macrophage polarization enhances the efficiency of chemotherapy. <i>Journal of Controlled Release</i> , 2020, 320, 293-303.	4.8	18
741	Chemo-physical Strategies to Advance the <i>in Vivo</i> Functionality of Targeted Nanomedicine: The Next Generation. <i>Journal of the American Chemical Society</i> , 2021, 143, 538-559.	6.6	148
742	MHC class I-independent activation of virtual memory CD8 T cells induced by chemotherapeutic agent-treated cancer cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 723-734.	4.8	23
743	Cancer immune resistance: can theories converge?. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 411-419.	1.1	13
744	PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. <i>Oncolimmunology</i> , 2020, 9, 1711650.	2.1	37
749	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. <i>JCI Insight</i> , 2018, 3, .	2.3	123
750	Clinical implications of monitoring nivolumab immunokinetics in non-“small cell lung cancer patients. <i>JCI Insight</i> , 2018, 3, .	2.3	156
751	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. <i>Journal of Clinical Investigation</i> , 2019, 130, 374-388.	3.9	43
752	Harnessing the Tumor Microenvironment for the Treatment of Double Hit Lymphoma. <i>Blood</i> , 2016, 128, 47-47.	0.6	2

#	ARTICLE	IF	CITATIONS
753	Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments. <i>International Journal of Particle Therapy</i> , 2018, 5, 84-93.	0.9	22
754	Knowing the tumour microenvironment to optimise immunotherapy. <i>Acta Otorhinolaryngologica Italica</i> , 2019, 39, 2-8.	0.7	16
755	Autophagy and Hallmarks of Cancer. <i>Critical Reviews in Oncogenesis</i> , 2018, 23, 247-267.	0.2	82
756	Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors. <i>Oncotarget</i> , 2017, 8, 5686-5691.	0.8	12
757	Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice. <i>Oncotarget</i> , 2017, 8, 48959-48971.	0.8	5
758	Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. <i>Oncotarget</i> , 2017, 8, 76290-76304.	0.8	23
759	Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. <i>Oncotarget</i> , 2018, 9, 3576-3589.	0.8	19
760	Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy. <i>Oncotarget</i> , 2020, 11, 294-299.	0.8	8
761	Amino acid deprivation promotes intestinal homeostasis through autophagy. <i>Oncotarget</i> , 2016, 7, 29877-29878.	0.8	2
762	Resistance to chemoimmunotherapy in non-small-cell lung cancer. , 2020, 3, 445-453.		3
763	Histone Deacetylase Inhibitors in Tumor Immunotherapy. <i>Current Medicinal Chemistry</i> , 2019, 26, 2990-3008.	1.2	32
764	Antibiotic Use Does Not Appear to Influence Response to Nivolumab. <i>Anticancer Research</i> , 2017, 37, 3195-3200.	0.5	83
765	Macrophages at the crossroads of anticancer strategies. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 1271-1283.	3.0	20
766	A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e112.	1.0	15
767	Undaria pinnatifida Fucoidan-Rich Extract Recovers Immunity of Immunosuppressed Mice. <i>Journal of Microbiology and Biotechnology</i> , 2020, 30, 439-447.	0.9	13
768	Current Status of Immunotherapy for Lung Cancer and Future Perspectives. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 14.	0.7	19
769	Are Cancer Patients at Higher Risk of Death with COVID-19? Are Cancer Patients at Higher Risk of Death with Coronavirus Disease-19?. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 49-51.	0.6	7
770	A critical review of outcomes of cancer during the COVID-19 pandemic. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 461-467.	0.1	3

#	ARTICLE	IF	CITATIONS
771	Role of Immunotherapy in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 479-489.	2.3	295
772	Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma. <i>Vaccines</i> , 2021, 9, 1118.	2.1	2
773	Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11221.	1.8	9
774	Unfolding the potential of anti-programmed cell death protein 1 blockade in Hodgkin lymphoma – combination and personalisation?. <i>British Journal of Haematology</i> , 2021, , .	1.2	2
775	Dual-ligated metal organic framework as novel multifunctional nanovehicle for targeted drug delivery for hepatic cancer treatment. <i>Scientific Reports</i> , 2021, 11, 19808.	1.6	19
776	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction. <i>Acta Biomedica Scientifica</i> , 2021, 6, 146-159.	0.1	0
777	Association between adenovirus infection and mortality outcome among pediatric patients after hematopoietic stem cell transplant. <i>Transplant Infectious Disease</i> , 2021, 23, e13742.	0.7	3
778	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. <i>European Journal of Cancer</i> , 2021, 158, 47-62.	1.3	32
779	Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 158, 123-132.	1.3	11
780	The Future in Ovarian Cancer: Advances in Immunotherapies. , 2017, , 143-168.		0
782	The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter. , 2017, 37, 5885-5891.		9
783	Relationship between tumor infiltrating lymphocytes and progression in triple negative breast cancer. <i>Ginecologia Ro</i> , 2018, 3, 28.	0.0	1
784	Advances in the Application of Intestinal Flora in Anti-tumor Therapy. <i>Journal of Nutritional Oncology</i> , 2019, 4, 59-66.	0.1	0
785	An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S53-S53.	0.7	5
786	Disease progression in non-small cell lung cancer on immune-checkpoint inhibition, what are the options?. <i>Precision Cancer Medicine</i> , 0, 2, 13-13.	1.8	1
790	Changes of proportions of circulating lymphocyte subsets in cancer patients after chemotherapy. <i>Translational Cancer Research</i> , 2021, 10, 4169-4179.	0.4	3
791	Angiogenesis Pathway in Kidney Renal Clear Cell Carcinoma and Its Prognostic Value for Cancer Risk Prediction. <i>Frontiers in Medicine</i> , 2021, 8, 731214.	1.2	4
792	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 441-450.	3.0	2

#	ARTICLE	IF	CITATIONS
793	Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, 2184, 233-263.	0.4	1
794	A [Pt(cis-1,3-diaminocycloalkane)Cl <sub>2</sub> ] analog exhibits hallmarks typical of immunogenic cell death inducers in model cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2022, 226, 111628.	1.5	12
795	Clinical Study on recurrent and metastatic head and neck cancer patients treated with Nivolumab. <i>Japanese Journal of Head and Neck Cancer</i> , 2020, 46, 278-283.	0.0	1
796	Cancer stem cells, plasticity, and drug resistance. , 2020, 3, 140-148.		0
799	Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021, 159, 125-132.	1.3	11
800	Epidemiological and molecular characterization of a novel adenovirus of squirrel monkeys after fatal infection during immunosuppression. <i>Microbial Genomics</i> , 2020, 6, .	1.0	1
801	Biphasic Increases of Cell Surface Calreticulin Following Treatment with Mitoxantrone. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1595-1599.	0.6	3
804	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, .		7
805	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 745769.	2.2	3
806	Kinase Inhibitorsâ€™ Effects on Innate Immunity in Solid Cancers. <i>Cancers</i> , 2021, 13, 5695.	1.7	5
807	Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12339.	1.8	23
808	Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. <i>Cancers</i> , 2021, 13, 5999.	1.7	6
809	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9031-9049.	0.8	0
810	Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach. <i>Cancers</i> , 2021, 13, 6016.	1.7	19
811	PD-1/PD-L1 Inhibitors Monotherapy for the Treatment of Endometrial Cancer: Meta-Analysis and Systematic Review. <i>Cancer Investigation</i> , 2022, 40, 293-309.	0.6	0
812	Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 773420.	1.3	10
813	Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. <i>European Journal of Cancer</i> , 2022, 160, 61-71.	1.3	29
814	PD-1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2022, 113, 399-410.	1.7	12

#	ARTICLE	IF	CITATIONS
815	Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. <i>Translational Research</i> , 2022, 241, 83-95.	2.2	12
816	Lung Cancer Subtype Diagnosis by Fusing Image-genomics Data and Hybrid Deep Networks. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2021, PP, 1-1.	1.9	6
817	Immunotherapy in Gastrointestinal Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 259-272.	0.8	3
818	Basics of immunotherapy for epithelial ovarian cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2022, 51, 102283.	0.6	4
819	A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy. <i>Biomaterials</i> , 2022, 281, 121334.	5.7	11
820	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. <i>Immunotherapy</i> , 2022, 14, 155-167.	1.0	7
821	Platinum(IV) complexes as inhibitors of CD47-SIRP $\alpha$ axis for chemoimmunotherapy of cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 229, 114047.	2.6	19
822	Engineered nanogels simultaneously implement HDAC inhibition and chemotherapy to boost antitumor immunity via pyroptosis. <i>Applied Materials Today</i> , 2022, 26, 101363.	2.3	9
823	Thermosensitive and tumor microenvironment activated nanotheranostics for the chemodynamic/photothermal therapy of colorectal tumor. <i>Journal of Colloid and Interface Science</i> , 2022, 612, 223-234.	5.0	41
825	The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues. <i>Frontiers in Oncology</i> , 2022, 12, 815726.	1.3	1
826	Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2117-2126.	2.0	1
827	Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions. <i>Cell Reports Methods</i> , 2022, 2, 100153.	1.4	9
828	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	1.8	15
829	Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 1560-1571.	3.2	33
830	Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. <i>Pharmaceutics</i> , 2022, 14, 209.	2.0	26
831	Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells. <i>Molecular Therapy</i> , 2022, 30, 1171-1187.	3.7	11
832	Fabrication of pH/Redox Dual-Responsive Mixed Polyprodrug Micelles for Improving Cancer Chemotherapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 802785.	1.6	5
833	Curcumin induces immunogenic cell death in murine colorectal carcinoma CT26 cells. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 2, 100046.	0.5	3

#	ARTICLE	IF	CITATIONS
834	Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 809304.	1.3	23
835	The rapidly evolving landscape of advanced gastric cancer therapy. <i>Future Oncology</i> , 2022, , .	1.1	1
836	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. <i>Biomedicines</i> , 2022, 10, 411.	1.4	11
837	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 <sup>+</sup> CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, e001650.		35
838	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53
839	Melanoma therapeutics: a literature review. <i>Journal of Biomedical Research</i> , 2022, 36, 77.	0.7	16
840	Multi-Omics Profiling of the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 283-326.	0.8	6
841	Combinatorial immunotherapy strategies for cancer vaccines. , 2022, , 137-154.		0
842	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. <i>Biomedicines</i> , 2022, 10, 537.	1.4	9
843	Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 1216.	1.7	12
844	Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. <i>Cells</i> , 2022, 11, 770.	1.8	26
845	Enhanced antitumor chemo-immunotherapy by local co-delivery of chemotherapeutics, immune checkpoint blocking antibody and IDO inhibitor using an injectable polypeptide hydrogel. <i>Journal of Polymer Science</i> , 2022, 60, 1595-1609.	2.0	9
846	Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2569.	1.8	11
847	Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3726-3738.	5.7	15
848	Predictive role of CYFRA 21-1 for S-1 monotherapy in non-small cell lung cancer patients. <i>Respiratory Investigation</i> , 2022, 60, 393-399.	0.9	4
849	Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 5022-5033.	0.7	4
850	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. <i>Nature Communications</i> , 2022, 13, 1487.	5.8	17
851	The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2022, , .	1.3	3

#	ARTICLE	IF	CITATIONS
852	Breaking Immunosuppressive Barriers by Engineered Nanoplatfoms for Turning Cold Tumor to Hot. <i>Advanced Therapeutics</i> , 2022, 5, .	1.6	3
853	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. <i>Journal of Hematology and Oncology</i> , 2022, 15, 24.	6.9	136
854	Redox signaling at the crossroads of human health and disease. <i>MedComm</i> , 2022, 3, e127.	3.1	44
855	Immunosuppressive tumor-associated macrophages expressing interleukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. , 2022, 10, e003416.		28
856	Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 21-35.	1.1	4
857	Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity. <i>Frontiers in Oncology</i> , 2022, 12, 764923.	1.3	4
858	Modulation of TLR/NF- $\kappa$ B/NLRP Signaling by Bioactive Phytochemicals: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 834072.	1.3	13
859	Identifying the Potential Role and Prognostic Value of the Platelet-Derived Growth Factor Pathway in Kidney Renal Clear Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	0
860	Conventional Therapies Deplete Brain-Infiltrating Adaptive Immune Cells in a Mouse Model of Group 3 Medulloblastoma Implicating Myeloid Cells as Favorable Immunotherapy Targets. <i>Frontiers in Immunology</i> , 2022, 13, 837013.	2.2	1
862	Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers. <i>Cancers</i> , 2022, 14, 1748.	1.7	22
863	A Target Animal Effectiveness Study on Adjuvant Peptide-Based Vaccination in Dogs with Non-Metastatic Appendicular Osteosarcoma Undergoing Amputation and Chemotherapy. <i>Cancers</i> , 2022, 14, 1347.	1.7	7
864	Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 802467.	1.3	4
865	Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3559.	1.8	15
866	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1687-1695.	1.6	10
867	Hyperprogressive disease in leiomyosarcoma: a threat to the use of single-agent anti-PD-(L)1 therapy?. <i>Immunotherapy</i> , 2022, 14, 271-274.	1.0	2
868	Neoadjuvant Therapy for Locally Advanced Esophageal Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 734581.	1.3	6
869	Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. <i>Journal of Controlled Release</i> , 2022, 345, 200-213.	4.8	13
870	Effective Disease Control After Combinatorial Treatment with a PD-1 Antibody and an mTOR Inhibitor for Recurrent Ovarian Clear Cell Carcinomas: A Case Report and Literature Review. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5429-5434.	1.0	3



#	ARTICLE	IF	CITATIONS
871	Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. <i>Nature Communications</i> , 2021, 12, 7041.	5.8	43
872	Endometrial cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 88.	18.1	155
874	Development of a nonhuman primate challenge model to evaluate CD8 <sup>+</sup> T cell responses to an adenovirus-based vaccine expressing SIV proteins upon repeat-dose treatment with checkpoint inhibitors. <i>MAbs</i> , 2022, 14, 1979447.	2.6	1
875	Low Expression of PLAT in Breast Cancer Infers Poor Prognosis and High Immune Infiltrating Level. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10213-10224.	0.8	4
876	Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2022, 2410, 649-670.	0.4	11
877	Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma. <i>Biomedicines</i> , 2021, 9, 1930.	1.4	2
878	Chemotherapy Effects on Immune System. , 2022, , 287-302.		3
880	Recent advances in organic and polymeric carriers for local tumor chemo-immunotherapy. <i>Science China Technological Sciences</i> , 2022, 65, 1011-1028.	2.0	7
881	Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2022, 13, 1391-1400.	0.8	6
911	IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin and paclitaxel, with or without bevacizumab in patients with advanced cancer. , 2022, 10, e003924.		8
912	Application of immune checkpoint inhibitors in colorectal cancer. <i>Journal of Central South University (Medical Sciences)</i> , 2021, 46, 894-899.	0.1	0
913	Immunogenic Cell Death in Cancer Therapy. , 2022, 14, 40-53.		12
915	Cisplatin plus anti-PD-1 antibody enhanced treatment efficacy in advanced esophageal squamous cell carcinoma.. <i>American Journal of Cancer Research</i> , 2022, 12, 451-468.	1.4	1
916	Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 2818-2829.	3.2	12
917	Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond. <i>Current Drug Targets</i> , 2022, 23, .	1.0	1
918	Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. <i>Cancer Cell International</i> , 2022, 22, 168.	1.8	36
919	Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses. <i>Journal of Infusion Nursing</i> , 2022, 45, 142-153.	1.2	2
920	Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0

#	ARTICLE	IF	CITATIONS
921	Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2308.	1.7	12
922	Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. <i>OncImmunology</i> , 2022, 11, 2066767.	2.1	9
923	A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy. <i>Materials Today Bio</i> , 2022, 14, 100284.	2.6	11
924	MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease. <i>Bladder Cancer</i> , 2022, 8, 269-276.	0.2	2
925	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. <i>Gut</i> , 2023, 72, 736-748.	6.1	42
926	NcRNAs-mediated P2RX1 expression correlates with clinical outcomes and immune infiltration in patients with breast invasive carcinoma. <i>Aging</i> , 2022, 14, 4471-4485.	1.4	2
927	Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	11
928	Nanoscale metal organic frameworks and their applications in disease diagnosis and therapy. <i>Microchemical Journal</i> , 2022, 180, 107595.	2.3	4
929	The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	94
931	Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE). <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	21
932	Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?. <i>Seminars in Cancer Biology</i> , 2022, 86, 834-850.	4.3	12
933	Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. <i>Advanced Science</i> , 2022, 9, .	5.6	140
934	Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
935	5-Fluorouracil Treatment of CT26 Colon Cancer Is Compromised by Combined Therapy with IMMODIN. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6374.	1.8	4
936	Distinct Gene Expression Profiles in Viable Hepatocellular Carcinoma Treated With Liver-Directed Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
937	Extracellular Vesicle-Based Drug Delivery Systems for Enhanced Antitumor Therapies through Modulating the Cancer Immunity Cycle. <i>Advanced Materials</i> , 2022, 34, .	11.1	43
938	Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
939	Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	10

#	ARTICLE	IF	CITATIONS
940	A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
941	Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
942	From Intestinal Epithelial Homeostasis to Colorectal Cancer: Autophagy Regulation in Cellular Stress. <i>Antioxidants</i> , 2022, 11, 1308.	2.2	2
943	DNA Base Pairingâ€Inspired Supramolecular Nanodrug Camouflaged by Cancerâ€Cell Membrane for Osteosarcoma Treatment. <i>Small</i> , 2022, 18, .	5.2	12
944	Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
945	Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology. <i>Cancers</i> , 2022, 14, 3352.	1.7	5
947	Promoting Best Practice in Cancer Care in Sub Saharan Africa. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
948	S100A14: A novel negative regulator of cancer stemness and immune evasion by inhibiting STAT3â€mediated programmed deathâ€ligand 1 expression in colorectal cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	7
949	Immune Checkpoint Inhibitors in Cancer Therapyâ€How to Overcome Drug Resistance?. <i>Cancers</i> , 2022, 14, 3575.	1.7	18
951	Immunology and immunotherapy in breast cancer. <i>Cancer Biology and Medicine</i> , 2022, 19, 609-618.	1.4	10
952	Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity. <i>British Journal of Cancer</i> , 2022, 127, 1584-1594.	2.9	21
953	Autophagy blockade potentiates cancerâ€associated immunosuppression through programmed death ligandâ€1 upregulation in bladder cancer. <i>Journal of Cellular Physiology</i> , 2022, 237, 3587-3597.	2.0	8
954	How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 1822.	1.4	11
955	Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	8
956	Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	31
957	Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade. <i>Cancers</i> , 2022, 14, 3690.	1.7	6
958	Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 981-998.	1.1	4
959	Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis. <i>Breast</i> , 2022, 66, 126-135.	0.9	4

#	ARTICLE	IF	CITATIONS
960	Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
961	PD-1/PD-L1 Blockade in Cancer Immunotherapy: Clinical Benefits, Limitations and Beyond. , 0, 8, 84-93.		0
962	Manipulating Offense and Defense Signaling to Fight Cold Tumors with Carrier-Free Nanoassembly of Fluorinated Prodrug and siRNA. <i>Advanced Materials</i> , 2022, 34, .	11.1	22
964	The implications from the interplay of neoadjuvant chemoradiotherapy and the immune microenvironment in rectal cancer. <i>Future Oncology</i> , 2022, 18, 3229-3244.	1.1	2
965	Progressive multifocal leukoencephalopathy associated with chemotherapy induced lymphocytopenia in solid tumors – case report of an underestimated complication. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
966	Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the PI3K/AKT pathway through the Serpinc1 gene. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
967	The –Yin and Yang–of Unfolded Protein Response in Cancer and Immunogenic Cell Death. <i>Cells</i> , 2022, 11, 2899.	1.8	3
968	Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy. <i>Journal of Controlled Release</i> , 2022, 350, 761-776.	4.8	30
969	A Novel Biological Nano Confinement Inhibits Cancer Metastasis. <i>Oncologie</i> , 2022, 24, 591-597.	0.2	0
970	Biotechnology applications in clinical trials. , 2022, , 163-195.		0
971	T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. <i>Cancers</i> , 2022, 14, 4246.	1.7	4
972	Recent advances in therapeutic strategies for triple-negative breast cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	145
975	Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination. <i>Cancers</i> , 2022, 14, 4464.	1.7	7
976	Augmented Antitumor Effect of Unripe <i>Rubus coreanus</i> Miquel Combined with Oxaliplatin in a Humanized PD-1/PD-L1 Knock-In Colorectal Cancer Mouse Model. <i>Cells</i> , 2022, 11, 2876.	1.8	2
977	First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis. <i>Journal of Immunotherapy</i> , 2022, 45, 407-414.	1.2	1
978	miR-acious new avenues for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
980	Loss of secreted gelsolin enhances response to anticancer therapies. , 2022, 10, e005245.		4
981	Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6

#	ARTICLE	IF	CITATIONS
982	Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
983	Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. <i>Nature Communications</i> , 2022, 13, .	5.8	18
984	Bibliometric analysis of research on immunogenic cell death in cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
985	ZIP1+ fibroblasts protect lung cancer against chemotherapy via connexin-43 mediated intercellular Zn <sup>2+</sup> transfer. <i>Nature Communications</i> , 2022, 13, .	5.8	4
986	Immunotherapies catering to the unmet medical need of cold colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
987	Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211336.	0.8	4
988	Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
989	Targeting the gut microbiota for cancer therapy. <i>Nature Reviews Cancer</i> , 2022, 22, 703-722.	12.8	61
990	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. <i>Biomedicines</i> , 2022, 10, 2628.	1.4	1
991	Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. <i>Molecular Cancer</i> , 2022, 21, .	7.9	29
992	DFT study of therapeutic potential of graphitic carbon nitride as a carrier for controlled release of melphalan: an anticancer drug. <i>Journal of Molecular Modeling</i> , 2022, 28, .	0.8	3
993	Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	0
994	Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
995	Monocyte programming by cancer therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
996	NF- $\kappa$ B-regulated VentX expression mediates tumoricidal effects of chemotherapeutics at noncytotoxic concentrations. <i>IScience</i> , 2022, 25, 105426.	1.9	2
997	pH-responsive nanoprodugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer. <i>Acta Biomaterialia</i> , 2022, 154, 497-509.	4.1	15
998	What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13217.	1.8	9
999	Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis. <i>OncImmunology</i> , 2022, 11, .	2.1	2

#	ARTICLE	IF	CITATIONS
1000	Excessive HSP70/TLR2 activation leads to remodeling of the tumor immune microenvironment to resist chemotherapy sensitivity of mFOLFOX in colorectal cancer. <i>Clinical Immunology</i> , 2022, 245, 109157.	1.4	4
1001	Adenocarcinoma of the uterine corpus and sarcomas of the uterus. , 2023, , 125-174.e30.		0
1002	Novel Insight into Blocking Cancer Metastasis by Biological Nano Confinement through Altering the Cancer Microenvironment. <i>Clinical Cancer Investigation Journal</i> , 2022, 11, 10-14.	0.2	4
1003	Immunological Effects of Conventional Anticancer Drugs. , 2022, , 1-13.		0
1004	Metabolic reprogramming of immune cells in pancreatic cancer progression. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113992.	2.5	17
1005	Safety and efficacy analysis of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer. <i>Immunotherapy</i> , 2022, 14, 1307-1313.	1.0	1
1006	Chemokine switch regulated by TGF- $\beta$ 1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy. <i>Oncolmmunology</i> , 2022, 11, .	2.1	7
1007	A 2D Porous Zinc-Organic Framework Platform for Loading of 5-Fluorouracil. <i>Inorganics</i> , 2022, 10, 202.	1.2	116
1008	Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 5209-5227.	3.3	5
1009	CAR T-cells for colorectal cancer immunotherapy: Ready to go?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
1010	An introduction to causal inference for pharmacometricians. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 27-40.	1.3	7
1011	Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1012	Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. <i>BMC Medicine</i> , 2022, 20, .	2.3	11
1014	Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1015	Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 5810.	1.7	3
1016	Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 177-195.	0.9	1
1017	Immunogenic Death of Hepatocellular Carcinoma Cells in Mice Expressing Caspase-Resistant ROCK1 Is Not Replicated by ROCK Inhibitors. <i>Cancers</i> , 2022, 14, 5943.	1.7	1
1018	Evaluation of the ability of fatty acid metabolism signature to predict response to neoadjuvant chemoradiotherapy and prognosis of patients with locally advanced rectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
1019	Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	8
1020	Ferritin Nanocaged Doxorubicin Potentiates Chemo-immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death. <i>Small Methods</i> , 2023, 7, .	4.6	10
1021	Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15031.	1.8	6
1022	Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma. <i>Esophagus</i> , 0, , .	1.0	1
1023	Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1024	Association of HLA-C 3'UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer. <i>Pharmaceutics</i> , 2022, 14, 2737.	2.0	4
1025	Neoadjuvant immunotherapy for resectable esophageal cancer: A review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1026	From targeted therapy to a novel way: Immunogenic cell death in lung cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
1027	Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1028	Macrophage Membrane-Coated Nano-Gemcitabine Promotes Lymphocyte Infiltration and Synergizes AntiPD-L1 to Restore the Tumoricidal Function. <i>ACS Nano</i> , 2023, 17, 322-336.	7.3	15
1029	Solubilized curcuminoid complex prevents extensive immunosuppression through immune restoration and antioxidant activity: Therapeutic potential against SARS-CoV-2 (COVID-19). <i>International Immunopharmacology</i> , 2023, 115, 109635.	1.7	3
1030	Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
1031	Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211383.	1.4	3
1032	The portrayal of macrophages as tools and targets: A paradigm shift in cancer management. <i>Life Sciences</i> , 2023, 316, 121399.	2.0	2
1033	Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. <i>Cancers</i> , 2023, 15, 321.	1.7	21
1034	Genomic study and lipidomic bioassay of <i>Leeuwenhoekiella parthenopeia</i> : A novel rare biosphere marine bacterium that inhibits tumor cell viability. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
1035	Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
1036	Highly triple-effective synergy based on tetrahedral DNA nanostructure-induced tumor vaccines for cancer therapy. <i>Materials and Design</i> , 2023, 226, 111584.	3.3	4

#	ARTICLE	IF	CITATIONS
1037	Telomerase: A prominent oncological target for development of chemotherapeutic agents. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115121.	2.6	5
1038	Harnessing immunotherapy to enhance the systemic anti-tumor effects of thermosensitive liposomes. <i>Drug Delivery and Translational Research</i> , 2023, 13, 1059-1073.	3.0	0
1040	Tumor immunology. , 2023, , 245-452.		0
1041	Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy. <i>Biomolecules</i> , 2023, 13, 190.	1.8	4
1042	Understanding the role of the gut microbiome in gastrointestinal cancer: A review. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	55
1043	Mechanisms driving the immunoregulatory function of cancer cells. <i>Nature Reviews Cancer</i> , 2023, 23, 193-215.	12.8	40
1044	Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1226-1233.	0.5	4
1045	PD-1/PD-L1 and DNA Damage Response in Cancer. <i>Cells</i> , 2023, 12, 530.	1.8	12
1046	Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1047	ESIPT-, AIE-, and AIE + ESIPT-Based Light-Activated Drug Delivery Systems and Bioactive Donors for Targeted Disease Treatment. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3732-3745.	2.9	5
1048	Liposomal ATM siRNA delivery for enhancing triple-negative breast cancer immune checkpoint blockade therapy. <i>Journal of Biomaterials Applications</i> , 2023, 37, 1835-1846.	1.2	1
1050	Prognostic and predictive impact of gene expression in nodeâ€positive early breast cancer patients receiving doseâ€dense versus standardâ€dose adjuvant chemotherapy. <i>Molecular Oncology</i> , 2023, 17, 1060-1075.	2.1	0
1051	Immunogenic cell death inducer peptides: A new approach for cancer therapy, current status and future perspectives. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114503.	2.5	3
1052	Review on the effect of chemotherapy on the intestinal barrier: Epithelial permeability, mucus and bacterial translocation. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114644.	2.5	10
1053	Distinct role of tumor-infiltrating lymphocytes between synchronous and metachronous colorectal cancer. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, .	0.8	0
1054	Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer. <i>Immunotherapy</i> , 2023, 15, 127-133.	1.0	0
1055	Tumor necrosis factor-Î±-inducible protein 8-like protein 3 (TIPE3): a novel prognostic factor in colorectal cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
1056	Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	18



#	ARTICLE	IF	CITATIONS
1057	Dynamics of Age- versus Therapy-Related Clonal Hematopoiesis in Long-term Survivors of Pediatric Cancer. <i>Cancer Discovery</i> , 2023, 13, 844-857.	7.7	12
1058	Doxorubicinâ€”An Agent with Multiple Mechanisms of Anticancer Activity. <i>Cells</i> , 2023, 12, 659.	1.8	58
1059	Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells. <i>Cancers</i> , 2023, 15, 1295.	1.7	2
1060	Tumor-Targeting NHCâ€”Au(I) Complex Induces Immunogenic Cell Death in Hepatocellular Carcinoma. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3934-3952.	2.9	13
1061	Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). <i>Lung Cancer</i> , 2023, 178, 191-197.	0.9	3
1062	Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study. <i>OncoTargets and Therapy</i> , 0, Volume 16, 157-163.	1.0	2
1063	Immune Compartments and Extracellular Matrix Crosstalk Involved in Tumor Dissemination. , 2023, , 1-22.		0
1064	Immune microenvironment in high-grade serous ovarian carcinomas: association with molecular profiles and neoadjuvant therapy outcome. <i>Voprosy Onkologii</i> , 2023, 69, 74-81.	0.1	0
1065	Immune Checkpoint and Tumor Therapy. , 0, , .		0
1066	Tamoxifen Modulates the Immune Landscape of the Tumour Microenvironment: The Paired Siglec-5/14 Checkpoint in Anti-Tumour Immunity in an In Vitro Model of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5512.	1.8	3
1067	Identification of LSM family members as potential chemoresistance predictive and therapeutic biomarkers for gastric cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1068	Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	32
1069	Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2023, 35, 166-177.	1.1	1
1070	Therapeutic Cancer Vaccines for Nonmelanoma Skin Cancer. <i>Current Treatment Options in Oncology</i> , 2023, 24, 496-514.	1.3	1
1071	Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor. <i>Liver Cancer</i> , 2023, 12, 281-288.	4.2	1
1072	Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects. , 2023, 40, .		0
1073	KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	4
1074	Can we cure relapsed/refractory Hodgkin lymphoma without a stem cell transplant?. <i>Haematologica</i> , 0, , .	1.7	0

#	ARTICLE	IF	CITATIONS
1075	Cytokine-Induced Killer Cell Immunotherapy Combined With Gemcitabine Reduces Systemic Metastasis in Pancreatic Cancer. <i>Pancreas</i> , 2022, 51, 1251-1257.	0.5	0
1076	Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1077	Transcriptomic insights into adenoid cystic carcinoma via RNA sequencing. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
1078	Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation. <i>Journal of Controlled Release</i> , 2023, 357, 531-544.	4.8	7
1079	Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	13
1080	Potential prognostic and immunotherapeutic value of calponin 1: A pan-cancer analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
1107	Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	0
1110	Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 92, 241-251.	1.1	1
1129	The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation. <i>Cell Death and Differentiation</i> , 2023, 30, 2447-2451.	5.0	2
1155	Immunotherapeutic strategies and immunotherapy resistance in prostate cancer. , 2024, , 235-253.		0
1163	The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 3953-3969.	2.0	0
1168	Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. <i>Nature Reviews Immunology</i> , 0, , .	10.6	2
1180	Immune System Influence on Hematopoietic Stem Cells and Leukemia Development. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 125-135.	0.8	0
1186	Radiobiology of proton therapy and its clinical implications. , 0, , .		0
1202	PD-1/PD-L1 Inhibitors for the Treatment of Lung Cancer. , 2024, , 65-86.		0